https://semaglutides.org/news/2026/#rule-702-general-causation-hearing-opens-mdl-3094-20262026-09-15T01:35:26Zweekly https://semaglutides.org/news/2026/#status-check-two-unreconciled-medicare-semaglutide-prices-2027-20262026-09-15T03:04:33Zweekly https://semaglutides.org/news/2026/#status-check-no-glp-1-injury-settlement-no-20262026-09-15T03:04:58Zweekly https://semaglutides.org/news/2026/#tga-counterfeit-retatrutide-eightfold-semaglutide-dose-20262026-09-15T03:32:11Zweekly https://semaglutides.org/news/2026/#mdl-3094-daubert-hearing-20262026-09-15T03:32:22Zweekly https://semaglutides.org/news/2026/#easd-2026-milan-sets-up-competitor-data-20262026-09-15T03:32:27Zweekly https://semaglutides.org/news/2026/#generic-liraglutide-cash-prices-run-three-eleven-times-20262026-09-15T03:32:49Zweekly https://semaglutides.org/news/2026/#label-check-what-current-zepbound-prescribing-information-actually-20262026-09-15T03:32:37Zweekly https://semaglutides.org/news/2026/#novo-38-percent-us-obesity-share-cmd-week-20262026-09-15T03:32:38Zweekly https://semaglutides.org/news/2026/#novo-nordisk-rebrands-novo-introduces-novo-way-20262026-09-15T03:32:36Zweekly https://semaglutides.org/news/2026/#roche-pharma-day-three-obesity-mechanisms-20262026-09-15T03:33:00Zweekly https://semaglutides.org/news/2026/#semaglutide-cash-prices-settle-149-499-band-while-20262026-09-15T03:32:57Zweekly https://semaglutides.org/news/2026/#sixteen-challenger-programs-phase-3-none-before-2027-20262026-09-15T03:33:17Zweekly https://semaglutides.org/news/2026/#status-check-balance-window-closes-january-one-committed-state-20262026-09-15T03:33:23Zweekly https://semaglutides.org/news/2026/#status-check-bridge-copays-excluded-from-part-d-affordability-mechanisms-20262026-09-15T03:33:13Zweekly https://semaglutides.org/news/2026/#status-check-no-balance-state-no-post-2027-medicare-answer-20262026-09-15T03:33:18Zweekly https://semaglutides.org/news/2026/#status-check-novo-675-list-price-above-every-negotiated-price-20262026-09-15T03:33:33Zweekly https://semaglutides.org/news/2026/#status-check-zepbound-caremark-class-action-live-as-restoration-nears-20262026-09-15T03:33:32Zweekly https://semaglutides.org/news/2026/#lean-mass-race-dozen-programs-one-approved-drug-20262026-09-15T03:33:50Zweekly https://semaglutides.org/news/2026/#tirzepatide-evidence-base-what-has-what-has-not-20262026-09-15T03:33:58Zweekly https://semaglutides.org/news/2026/#state-of-play-september-20262026-09-15T03:33:59Zweekly https://semaglutides.org/news/2026/#aetna-posts-zepbound-formulary-addition-effective-october-20262026-09-15T04:24:18Zweekly https://semaglutides.org/news/2026/#amgen-maritide-readouts-outside-2026-window-20262026-09-15T04:24:31Zweekly https://semaglutides.org/news/2026/#astrazeneca-obesity-case-two-fall-readouts-20262026-09-15T04:24:52Zweekly https://semaglutides.org/news/2026/#baseline-keyword-serp-landscape-captured-semaglutides-org-20262026-09-15T04:24:34Zweekly https://semaglutides.org/news/2026/#branded-tirzepatide-self-pay-prices-sit-far-below-20262026-09-15T04:24:41Zweekly https://semaglutides.org/news/2026/#china-semaglutide-generics-stuck-data-exclusivity-20262026-09-15T04:25:00Zweekly https://semaglutides.org/news/2026/#chinese-licensing-sets-price-of-entry-obesity-20262026-09-15T04:25:17Zweekly https://semaglutides.org/news/2026/#cms-2027-medicare-landscape-still-pending-before-open-enrollment-20262026-09-15T04:25:06Zweekly https://semaglutides.org/news/2026/#corbus-canyon-1-topline-crb-913-20262026-09-15T04:24:53Zweekly https://semaglutides.org/news/2026/#india-generic-semaglutide-price-war-six-months-on-20262026-09-15T04:25:22Zweekly https://semaglutides.org/news/2026/#mazdutide-us-path-theoretical-lilly-phase-2-published-20262026-09-15T04:25:06Zweekly https://semaglutides.org/news/2026/#pfizer-obesity-case-rests-on-monthly-injectable-20262026-09-15T04:25:31Zweekly https://semaglutides.org/news/2026/#status-check-globe-guard-drug-pricing-model-rules-unfinalized-20262026-09-15T04:25:39Zweekly https://semaglutides.org/news/2026/#status-check-marketplace-weakest-glp-1-coverage-channel-2027-20262026-09-15T04:25:33Zweekly https://semaglutides.org/news/2026/#status-check-pbm-delinking-does-not-bite-until-2028-20262026-09-15T04:25:25Zweekly https://semaglutides.org/news/2026/#survodutide-heads-to-easd-without-filing-date-20262026-09-15T04:25:47Zweekly https://semaglutides.org/news/2026/#compounding-fight-state-of-play-september-20262026-09-15T04:26:13Zweekly https://semaglutides.org/news/2026/#viking-vk2735-maintenance-data-outstanding-readout-20262026-09-15T04:26:15Zweekly https://semaglutides.org/news/2026/#canadian-grocers-generic-semaglutide-pharmacy-volumes-20262026-09-15T04:25:49Zweekly https://semaglutides.org/news/2026/#glp1-bipolar-hospitalization-20262026-09-15T04:25:53Zweekly https://semaglutides.org/news/2026/#novo-aligns-ozempic-price-with-canadian-generics-20262026-09-15T04:25:57Zweekly https://semaglutides.org/news/2026/#wegovy-pill-four-to-one-lead-over-foundayo-20262026-09-15T04:26:29Zweekly https://semaglutides.org/news/2026/#ukraine-charges-27-falsified-tirzepatide-ring-20262026-09-15T04:26:08Zweekly https://semaglutides.org/news/2026/#largest-musculoskeletal-synthesis-date-no-bone-joint-effect-20262026-09-15T03:33:52Zweekly https://semaglutides.org/news/2026/#musculoskeletal-meta-analysis-1-25-million-people-finds-20262026-09-15T03:34:01Zweekly https://semaglutides.org/news/2026/#meta-analysis-links-glp-1-drugs-lean-mass-20262026-09-15T04:26:09Zweekly https://semaglutides.org/news/2026/#penn-researchers-publish-ai-study-400-000-glp-20262026-09-15T04:26:15Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-tally-32-glp-1-peptides-20262026-09-15T04:26:31Zweekly https://semaglutides.org/news/2026/#fda-approves-scholar-rock-apitegromab-isembyld-20262026-09-15T03:34:00Zweekly https://semaglutides.org/news/2026/#lillys-tirzepatide-reaches-57-glp-1-market-20262026-09-15T03:34:17Zweekly https://semaglutides.org/news/2026/#wernicke-encephalopathy-signal-semaglutide-tirzepatide-20262026-09-15T03:34:23Zweekly https://semaglutides.org/news/2026/#review-finds-mfn-drugmakers-hold-section-232-tariff-relief-until-2029-20262026-09-15T03:34:33Zweekly https://semaglutides.org/news/2026/#aarp-briefs-members-bridge-savings-ahead-of-open-enrollment-20262026-09-15T04:26:46Zweekly https://semaglutides.org/news/2026/#semaglutide-patent-cliff-analysis-20262026-09-15T04:26:40Zweekly https://semaglutides.org/news/2026/#fda-approves-isembyld-apitegromab-first-myostatin-inhibitor-20262026-09-15T04:26:54Zweekly https://semaglutides.org/news/2026/#jp-morgan-resumes-hims-coverage-neutral-20262026-09-15T04:26:35Zweekly https://semaglutides.org/news/2026/#lilly-shares-close-1-115-70-market-value-20262026-09-15T04:26:55Zweekly https://semaglutides.org/news/2026/#mfn-deal-state-pushback-medwatch-20262026-09-15T04:26:53Zweekly https://semaglutides.org/news/2026/#oral-glp1-tracker-september-20262026-09-15T04:26:51Zweekly https://semaglutides.org/news/2026/#wegovy-pill-foundayo-both-hit-record-weekly-prescriptions-20262026-09-15T04:26:58Zweekly https://semaglutides.org/news/2026/#china-approves-wegovy-mash-20262026-09-15T03:34:33Zweekly https://semaglutides.org/news/2026/#seventh-circuit-retatrutide-argument-preview-september-20262026-09-15T03:34:30Zweekly https://semaglutides.org/news/2026/#weight-regain-model-20262026-09-15T04:28:19Zweekly https://semaglutides.org/news/2026/#lilly-glp1-windfall-womens-health-push-20262026-09-15T04:27:17Zweekly https://semaglutides.org/news/2026/#cell-reports-asprosin-obesity-memory-explains-regain-20262026-09-15T04:27:08Zweekly https://semaglutides.org/news/2026/#current-obesity-names-engagement-unsolved-problem-digital-obesity-20262026-09-15T04:27:19Zweekly https://semaglutides.org/news/2026/#foundayo-prescriber-base-8000-to-36000-20262026-09-15T04:27:26Zweekly https://semaglutides.org/news/2026/#lilly-china-93-percent-growth-international-share-20262026-09-15T04:27:16Zweekly https://semaglutides.org/news/2026/#lilly-refers-200-entities-regulators-law-enforcement-20262026-09-15T04:27:23Zweekly https://semaglutides.org/news/2026/#frontiers-review-divergent-ocular-safety-across-glp-1-drugs-20262026-09-15T04:27:26Zweekly https://semaglutides.org/news/2026/#umbrella-review-quantifies-glp-1-drugs-insulin-adjuncts-20262026-09-15T04:27:49Zweekly https://semaglutides.org/news/2026/#nmpa-accepts-hengrui-ribupatide-filing-t2d-20262026-09-15T03:34:37Zweekly https://semaglutides.org/news/2026/#endocrine-society-obesity-scientific-statement-center-on-obesity-20262026-09-15T03:34:45Zweekly https://semaglutides.org/news/2026/#analysis-puts-tirzepatide-nearly-two-thirds-lillys-quarterly-20262026-09-15T04:27:39Zweekly https://semaglutides.org/news/2026/#medscape-tirzepatide-beats-semaglutide-weight-not-safety-20262026-09-15T04:27:50Zweekly https://semaglutides.org/news/2026/#forbes-says-administration-left-pbms-largely-untouched-20262026-09-15T04:27:42Zweekly https://semaglutides.org/news/2026/#clark-hill-guidance-fifth-circuit-tirzepatide-compounding-20262026-09-15T04:27:48Zweekly https://semaglutides.org/news/2026/#morgan-stanley-downgrade-20262026-09-15T04:29:57Zweekly https://semaglutides.org/news/2026/#novo-q3-ziltivekimab-impairment-view-20262026-09-15T04:28:05Zweekly https://semaglutides.org/news/2026/#mounjaro-cv-nod-physician-views-20262026-09-15T04:28:01Zweekly https://semaglutides.org/news/2026/#foodnavigator-glp-1-messaging-consumers-more-selective-20262026-09-15T04:28:07Zweekly https://semaglutides.org/news/2026/#zealand-zupreme-2-marked-completed-20262026-09-15T04:28:30Zweekly https://semaglutides.org/news/2026/#truveta-19-percent-jump-glp-1-prescribing-seniors-after-bridge-20262026-09-15T01:36:17Zweekly https://semaglutides.org/news/2026/#aleniglipron-open-label-extension-16-2-weight-loss-20262026-09-15T03:34:56Zweekly https://semaglutides.org/news/2026/#cms-bridge-prior-authorization-under-12-hours-no-formal-appeal-20262026-09-15T03:34:59Zweekly https://semaglutides.org/news/2026/#ers-2026-semaglutide-tied-40-percent-fewer-asthma2026-09-15T03:35:01Zweekly https://semaglutides.org/news/2026/#lilly-mochi-conspiracy-claims-trimmed-september-20262026-09-15T03:35:05Zweekly https://semaglutides.org/news/2026/#novo-shuts-two-more-ziltivekimab-heart-trials-20262026-09-15T03:35:06Zweekly https://semaglutides.org/news/2026/#amycretin-late-stage-20262026-09-15T03:35:18Zweekly https://semaglutides.org/news/2026/#sandoz-canada-generic-semaglutide-launch-excludes-glp1-targets-20262026-09-15T03:35:25Zweekly https://semaglutides.org/news/2026/#novo-capital-markets-day-preview-analysts-20262026-09-15T04:28:34Zweekly https://semaglutides.org/news/2026/#obesity-market-forecast-20262026-09-15T04:28:29Zweekly https://semaglutides.org/news/2026/#cms-limited-bridge-outreach-manufacturers-advertise-program-20262026-09-15T04:28:57Zweekly https://semaglutides.org/news/2026/#eight-generic-semaglutide-files-health-canada-20262026-09-15T04:29:08Zweekly https://semaglutides.org/news/2026/#gallup-revises-2026-glp-1-obesity-estimates2026-09-15T04:28:51Zweekly https://semaglutides.org/news/2026/#emarketer-glp-1-use-reshapes-whole-household-habits-20262026-09-15T04:28:56Zweekly https://semaglutides.org/news/2026/#moonwalk-raises-70m-adipose-rnai-obesity-20262026-09-15T04:28:48Zweekly https://semaglutides.org/news/2026/#novo-shares-ziltivekimab-halt-outweighs-step-young-20262026-09-15T04:28:54Zweekly https://semaglutides.org/news/2026/#novo-share-performance-sept-20262026-09-15T04:29:04Zweekly https://semaglutides.org/news/2026/#zepbound-cost-offset-published-numbers-dom-20262026-09-15T04:29:27Zweekly https://semaglutides.org/news/2026/#peerj-meta-analysis-confirms-regain-withdrawal-improvement-side-20262026-09-15T04:29:13Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-clinical-data-oral-small-molecule-amylin-20262026-09-15T04:29:19Zweekly https://semaglutides.org/news/2026/#three-guided-q3-obesity-milestones-still-open-20262026-09-15T04:29:30Zweekly https://semaglutides.org/news/2026/#step-young-obesityweek-20262026-09-15T01:36:03Zweekly https://semaglutides.org/news/2026/#lilly-us-manufacturing-passes-50-billion-20262026-09-15T04:29:26Zweekly https://semaglutides.org/news/2026/#mounjaro-india-top-selling-drug-tirzepatide-share-20262026-09-15T04:29:38Zweekly https://semaglutides.org/news/2026/#semaglutide-tirzepatide-equivalent-weight-loss-type-2-diabetes-20262026-09-15T04:29:35Zweekly https://semaglutides.org/news/2026/#no-final-503b-bulks-determination-september-20262026-09-15T04:29:35Zweekly https://semaglutides.org/news/2026/#north-carolina-confirms-no-restoration-state-employee-glp-20262026-09-15T04:29:45Zweekly https://semaglutides.org/news/2026/#medicare-second-negotiation-round-savings-20262026-09-15T04:29:45Zweekly https://semaglutides.org/news/2026/#medicaid-obesity-coverage-count-twelve-states-falling-october-20262026-09-15T03:35:38Zweekly https://semaglutides.org/news/2026/#hims-waitlist-149-wegovy-ozempic-novo-partnership-20262026-09-15T04:30:07Zweekly https://semaglutides.org/news/2026/#lillydirect-self-pay-ladder-refill-condition-confirmed-20262026-09-15T04:29:53Zweekly https://semaglutides.org/news/2026/#weightwatchers-lillydirect-med-plus-nationwide-20262026-09-15T04:30:11Zweekly https://semaglutides.org/news/2026/#zepbound-savings-card-2026-terms-tighter-caps-confirmed-20262026-09-15T04:30:05Zweekly https://semaglutides.org/news/2026/#novo-halts-hermes-athena-ziltivekimab-trials-20262026-09-15T03:05:01Zweekly https://semaglutides.org/news/2026/#foundayo-reaches-44-000-weekly-scripts-oral-glp-20262026-09-15T03:35:38Zweekly https://semaglutides.org/news/2026/#patient-injury-suits-mochi-supplier-network-pharmacies-20262026-09-15T03:35:33Zweekly https://semaglutides.org/news/2026/#pediatric-glp1-prescribing-study-20262026-09-15T03:35:41Zweekly https://semaglutides.org/news/2026/#retatrutide-30-3-average-weight-loss-triumph-1-20262026-09-15T03:35:45Zweekly https://semaglutides.org/news/2026/#washington-shuts-aequita-pharmacy-mochi-supply-chain-20262026-09-15T03:36:01Zweekly https://semaglutides.org/news/2026/#novo-begins-phase-3-two-cagrilintide-presentations-20262026-09-15T04:30:18Zweekly https://semaglutides.org/news/2026/#california-sb-1089-sent-governor-20262026-09-15T03:36:10Zweekly https://semaglutides.org/news/2026/#novo-united-labs-ubt251-phase-2-19-7-percent-20262026-09-15T03:36:11Zweekly https://semaglutides.org/news/2026/#nyu-genetic-study-links-glp1r-activity-male-pattern-hair-loss-20262026-09-15T03:36:10Zweekly https://semaglutides.org/news/2026/#easo-position-statement-incretin-therapies-comprehensive-obesity-care-20262026-09-15T04:30:13Zweekly https://semaglutides.org/news/2026/#fda-shortage-record-still-lists-liraglutide-shortage-while-20262026-09-15T04:30:15Zweekly https://semaglutides.org/news/2026/#menarini-licenses-gan-lee-bofanglutide-europe-20262026-09-15T04:30:47Zweekly https://semaglutides.org/news/2026/#novo-wins-copycat-pharmacy-false-ad-suit-20262026-09-15T04:30:33Zweekly https://semaglutides.org/news/2026/#state-licensing-boards-warning-notices-ruo-peptides-20262026-09-15T04:30:38Zweekly https://semaglutides.org/news/2026/#only-indiana-commits-balance-medicaid-model-29-states-decline-20262026-09-15T03:05:06Zweekly https://semaglutides.org/news/2026/#modern-healthcare-documents-employer-glp-1-retreat-cigna-pwc-starbucks-20262026-09-15T03:36:15Zweekly https://semaglutides.org/news/2026/#nature-late-life-semaglutide-extends-lifespan-female-mice-20262026-09-15T03:36:20Zweekly https://semaglutides.org/news/2026/#starbucks-ends-glp-1-weight-loss-coverage-october-20262026-09-15T03:36:27Zweekly https://semaglutides.org/news/2026/#medicare-bridge-blockbuster-revenue-lilly-analyst-20262026-09-15T04:30:39Zweekly https://semaglutides.org/news/2026/#fda-screens-glp-1-ingredients-at-border-fake-pharmacy-labels-20262026-09-15T04:30:32Zweekly https://semaglutides.org/news/2026/#oac-presses-pepsico-starbucks-to-keep-glp-1-coverage-20262026-09-15T04:30:41Zweekly https://semaglutides.org/news/2026/#poison-control-surge-unapproved-glp-1-products-20262026-09-15T04:30:53Zweekly https://semaglutides.org/news/2026/#september-pricing-snapshot-lillydirect-pens-vials-20262026-09-15T04:31:07Zweekly https://semaglutides.org/news/2026/#upper-macungie-final-approval-lilly-fogelsville-20262026-09-15T04:31:10Zweekly https://semaglutides.org/news/2026/#fda-updates-unapproved-glp-1-guidance-compounded-tirzepatide-20262026-09-15T03:04:54Zweekly https://semaglutides.org/news/2026/#glp-1-injury-dockets-reach-4-022-216-20262026-09-15T03:05:03Zweekly https://semaglutides.org/news/2026/#fda-green-list-import-alert-fraudulent-compounded-labels-20262026-09-15T03:36:35Zweekly https://semaglutides.org/news/2026/#fda-posts-batch-warning-letters-online-peptide-sellers-20262026-09-15T03:36:44Zweekly https://semaglutides.org/news/2026/#fifth-circuit-semaglutide-delisting-opinion-september-20262026-09-15T03:36:51Zweekly https://semaglutides.org/news/2026/#glp1-litigation-september-20262026-09-15T03:36:49Zweekly https://semaglutides.org/news/2026/#jpml-count-4-022-pending-mdl-3094-216-20262026-09-15T03:36:51Zweekly https://semaglutides.org/news/2026/#kff-poll-one-third-aware-trumprx-most-doubt-price-policies-20262026-09-15T03:37:03Zweekly https://semaglutides.org/news/2026/#lilly-cuts-foundayo-self-pay-prices-two-doses-20262026-09-15T03:37:05Zweekly https://semaglutides.org/news/2026/#20-drugmakers-have-drug-pricing-agreements-20262026-09-15T03:37:17Zweekly https://semaglutides.org/news/2026/#wegovy-pill-germany-launch-20262026-09-15T03:37:22Zweekly https://semaglutides.org/news/2026/#hims-securities-class-action-velanki-filed-20262026-09-15T03:37:20Zweekly https://semaglutides.org/news/2026/#unitedhealthcares-updated-weight-loss-prior-authorization-program-takes-20262026-09-15T03:37:22Zweekly https://semaglutides.org/news/2026/#mounjaro-heart-label-payer-leverage-analysis-20262026-09-15T04:30:57Zweekly https://semaglutides.org/news/2026/#bmj-canada-250-dollar-patent-fee-lapse-20262026-09-15T04:31:00Zweekly https://semaglutides.org/news/2026/#esc-2026-tirzepatide-maintenance-20262026-09-15T04:31:10Zweekly https://semaglutides.org/news/2026/#npj-higher-semaglutide-dose-fewer-neuropsychiatric-events-20262026-09-15T04:31:11Zweekly https://semaglutides.org/news/2026/#mash-outcomes-master-protocol-including-tirzepatide-recruiting-20262026-09-15T04:31:20Zweekly https://semaglutides.org/news/2026/#novo-haegebarth-global-research-petersen-external-innovation-20262026-09-15T04:31:22Zweekly https://semaglutides.org/news/2026/#pfizer-starts-september-berobenatide-phase-3-trials-20262026-09-15T04:31:55Zweekly https://semaglutides.org/news/2026/#reuters-company-by-company-reference-glp-1-pricing-deal-terms-20262026-09-15T04:31:30Zweekly https://semaglutides.org/news/2026/#time-reports-mfn-medicaid-prices-not-lowest-for-consumers-20262026-09-15T04:31:28Zweekly https://semaglutides.org/news/2026/#virtual-glp-1-program-strength-coaching-improves-both-20262026-09-15T04:31:32Zweekly https://semaglutides.org/news/2026/#rule-702-expert-hearing-tests-whether-glp-1-20262026-09-15T03:05:11Zweekly https://semaglutides.org/news/2026/#five-semaglutide-presentations-now-market-once-20262026-09-15T03:37:34Zweekly https://semaglutides.org/news/2026/#generic-liraglutide-undercuts-every-branded-glp-1-acquisition-20262026-09-15T03:37:39Zweekly https://semaglutides.org/news/2026/#semaglutide-indication-map-20262026-09-15T03:37:45Zweekly https://semaglutides.org/news/2026/#wegovy-self-pay-prices-20262026-09-15T03:37:47Zweekly https://semaglutides.org/news/2026/#lilly-fda-retatrutide-appeal-20262026-09-15T04:31:44Zweekly https://semaglutides.org/news/2026/#compounded-price-gap-20262026-09-15T04:31:33Zweekly https://semaglutides.org/news/2026/#mdl-3094-4000-cases-20262026-09-15T04:31:49Zweekly https://semaglutides.org/news/2026/#jama-pediatrics-biliary-events-youth-glp-1-20262026-09-15T04:31:53Zweekly https://semaglutides.org/news/2026/#glp1-liability-estimates-20262026-09-15T04:31:55Zweekly https://semaglutides.org/news/2026/#mash-semaglutide-only-20262026-09-15T04:32:07Zweekly https://semaglutides.org/news/2026/#ajmc-glp-1-linked-lower-obesity-related-cancer-risk-20262026-09-15T04:32:17Zweekly https://semaglutides.org/news/2026/#wegovy-hfpef-review-20262026-09-15T04:32:06Zweekly https://semaglutides.org/news/2026/#zenagamtide-naming-20262026-09-15T04:32:25Zweekly https://semaglutides.org/news/2026/#medicare-glp-1-bridge-enrollment-passes-half-million-20262026-09-15T03:05:28Zweekly https://semaglutides.org/news/2026/#brazil-clears-two-more-semaglutide-pens-interchangeable-20262026-09-15T03:37:57Zweekly https://semaglutides.org/news/2026/#guardian-gray-market-retatrutide-patients-20262026-09-15T03:37:57Zweekly https://semaglutides.org/news/2026/#mfn-agreements-reach-26-manufacturers-89-percent-branded-market-20262026-09-15T03:38:01Zweekly https://semaglutides.org/news/2026/#house-bill-10185-part-d-premium-credit-2027-20262026-09-15T04:32:13Zweekly https://semaglutides.org/news/2026/#adjust-t1d-extension-shows-glycemic-gains-fade-stopping-20262026-09-15T04:32:12Zweekly https://semaglutides.org/news/2026/#brazil-glp-1-smuggling-seizures-triple-20262026-09-15T04:32:25Zweekly https://semaglutides.org/news/2026/#hims-hers-launches-branded-glp-1s-australia-20262026-09-15T04:32:23Zweekly https://semaglutides.org/news/2026/#lilly-buys-merida-20262026-09-15T04:32:32Zweekly https://semaglutides.org/news/2026/#lilly-foundayos-big-consumer-ad-campaign-fronted-martha-20262026-09-15T04:32:52Zweekly https://semaglutides.org/news/2026/#lilly-registers-2001-patient-orforglipron-overweight-trial-20262026-09-15T04:32:35Zweekly https://semaglutides.org/news/2026/#taltz-zepbound-one-year-20262026-09-15T04:32:38Zweekly https://semaglutides.org/news/2026/#penn-glp1-male-pattern-hair-loss-study-20262026-09-15T04:32:56Zweekly https://semaglutides.org/news/2026/#brazil-glp1-black-market-reuters-20262026-09-15T04:32:45Zweekly https://semaglutides.org/news/2026/#glp1-low-starter-doses-effective-reuters-20262026-09-15T04:32:58Zweekly https://semaglutides.org/news/2026/#sciwind-ecnoglutide-phase-3-knee-osteoarthritis-20262026-09-15T04:33:08Zweekly https://semaglutides.org/news/2026/#sun-pharma-secures-section-232-tariff-relief-pricing-agreement-20262026-09-15T04:33:15Zweekly https://semaglutides.org/news/2026/#zepbound-label-revision-keeps-dual-weight-sleep-apnea-20262026-09-15T04:33:02Zweekly https://semaglutides.org/news/2026/#ascletis-doses-first-patient-global-phase-3-asc30-20262026-09-15T03:38:08Zweekly https://semaglutides.org/news/2026/#esc-2026-heart-failure-guideline-backs-semaglutide-tirzepatide-hfpef-20262026-09-15T03:38:12Zweekly https://semaglutides.org/news/2026/#large-cohort-compares-glp-1-drugs-spironolactone-resistant-20262026-09-15T04:33:14Zweekly https://semaglutides.org/news/2026/#novo-esc-2026-oral-semaglutide-organ-protection2026-09-15T04:33:21Zweekly https://semaglutides.org/news/2026/#lilly-cardiovascular-indication-dual-gip-glp-1-agonist-20262026-09-15T03:05:27Zweekly https://semaglutides.org/news/2026/#lilly-mounjaro-heart-indication-built-head-head-trial-20262026-09-15T03:05:44Zweekly https://semaglutides.org/news/2026/#mounjaro-cv-filing-20262026-09-15T03:05:34Zweekly https://semaglutides.org/news/2026/#foundayo-passes-40-000-weekly-prescriptions-20262026-09-15T04:33:15Zweekly https://semaglutides.org/news/2026/#google-updates-site-reputation-abuse-guidance-editorially-overseen-20262026-09-15T04:33:28Zweekly https://semaglutides.org/news/2026/#india-generics-struggle-20262026-09-15T04:33:35Zweekly https://semaglutides.org/news/2026/#fda-approves-mounjaro-cardiovascular-indication-20262026-09-15T03:05:40Zweekly https://semaglutides.org/news/2026/#fifth-circuit-upholds-fdas-glp-1-shortage-delistings-20262026-09-15T03:05:39Zweekly https://semaglutides.org/news/2026/#novo-confirms-2027-us-list-price-cut-20262026-09-15T03:38:14Zweekly https://semaglutides.org/news/2026/#researchers-propose-adaptive-maintenance-framework-beyond-continue-stop-20262026-09-15T03:38:30Zweekly https://semaglutides.org/news/2026/#william-blair-maps-rest-of-2026-obesity-catalysts-20262026-09-15T03:38:28Zweekly https://semaglutides.org/news/2026/#china-nmpa-accepts-wegovy-pill-filing-20262026-09-15T04:33:38Zweekly https://semaglutides.org/news/2026/#eudravigilance-analysis-compares-suicide-self-injury-glp-1-20262026-09-15T04:33:36Zweekly https://semaglutides.org/news/2026/#fifth-circuit-record-lilly-23-billion-capacity-20262026-09-15T04:33:32Zweekly https://semaglutides.org/news/2026/#both-tirzepatide-labels-updated-basis-surpass-cvot-20262026-09-15T03:38:35Zweekly https://semaglutides.org/news/2026/#court-lets-zepbound-formulary-lawsuit-against-cvs-caremark-20262026-09-15T03:38:39Zweekly https://semaglutides.org/news/2026/#cvs-walgreens-each-fill-100000-medicare-bridge-prescriptions-20262026-09-15T03:38:41Zweekly https://semaglutides.org/news/2026/#kff-estimates-medicare-bridge-cost-1-3-to-10-billion-20262026-09-15T03:38:48Zweekly https://semaglutides.org/news/2026/#real-world-analysis-finds-gray-market-retatrutide-underperforms-20262026-09-15T03:39:02Zweekly https://semaglutides.org/news/2026/#abbvie-phase-2-amylin-analog-abbv-295-20262026-09-15T04:33:40Zweekly https://semaglutides.org/news/2026/#glp-1-medicines-force-rethink-obesity-eating-disorder-care-20262026-09-15T04:33:46Zweekly https://semaglutides.org/news/2026/#glp1-construction-wave-lilly-site-detail-20262026-09-15T04:33:53Zweekly https://semaglutides.org/news/2026/#digital-engagement-linked-persistence-persistence-results-20262026-09-15T04:33:57Zweekly https://semaglutides.org/news/2026/#ftc-complaint-names-fifteen-ad-platforms-hims-tracking-20262026-09-15T04:34:05Zweekly https://semaglutides.org/news/2026/#jama-psychiatry-glp-1-mortality-serious-mental-illness-20262026-09-15T04:34:01Zweekly https://semaglutides.org/news/2026/#zepbound-healthcare-costs-study-20262026-09-15T04:33:57Zweekly https://semaglutides.org/news/2026/#meta-analysis-pools-real-world-incretin-results-bariatric-20262026-09-15T04:34:12Zweekly https://semaglutides.org/news/2026/#obesity-action-coalition-assesses-bridge-opening-weeks-troa-cosponsors-20262026-09-15T04:34:10Zweekly https://semaglutides.org/news/2026/#walgreens-says-half-of-bridge-patients-new-to-glp-1s-20262026-09-15T04:34:20Zweekly https://semaglutides.org/news/2026/#white-house-prepares-medicaid-mfn-deals-midsize-biotechs-20262026-09-15T04:34:18Zweekly https://semaglutides.org/news/2026/#fda-records-novo-nordisk-notice-saxenda-will-discontinued-20262026-09-15T03:05:59Zweekly https://semaglutides.org/news/2026/#kff-documents-medicare-bridge-excludes-5-9-million-sicker-patients-20262026-09-15T03:05:51Zweekly https://semaglutides.org/news/2026/#business-group-health-14-percent-employers-dropping-glp-1-2027-20262026-09-15T03:38:55Zweekly https://semaglutides.org/news/2026/#chipotle-shake-shack-smoothie-king-run-glp-1-20262026-09-15T03:38:59Zweekly https://semaglutides.org/news/2026/#four-glp1-decisions-20262026-09-15T03:39:09Zweekly https://semaglutides.org/news/2026/#large-employer-glp-1-coverage-falls-60-72-20262026-09-15T03:39:12Zweekly https://semaglutides.org/news/2026/#pepsico-drops-employee-weight-loss-drug-coverage-october-20262026-09-15T03:39:12Zweekly https://semaglutides.org/news/2026/#va-dod-guideline-discourages-stopping-effective-obesity-medication-20262026-09-15T03:39:27Zweekly https://semaglutides.org/news/2026/#genentech-hanmi-deal-20262026-09-15T04:34:36Zweekly https://semaglutides.org/news/2026/#foundayo-type-2-diabetes-decision-q4-2026-window2026-09-15T04:34:22Zweekly https://semaglutides.org/news/2026/#veteran-analysis-glp-1-fewer-overdoses-drug-related-deaths-20262026-09-15T04:34:27Zweekly https://semaglutides.org/news/2026/#fda-issues-batch-peptide-warning-letters-naming-tirzepatide-20262026-09-15T03:39:29Zweekly https://semaglutides.org/news/2026/#fda-tallies-1-700-adverse-event-naming-compounded-20262026-09-15T03:39:29Zweekly https://semaglutides.org/news/2026/#lilly-novo-nad-challenges-glp-1-copycat-ads-20262026-09-15T03:39:33Zweekly https://semaglutides.org/news/2026/#novo-nordisk-opens-zenagamtide-phase-3-trial-20262026-09-15T03:39:44Zweekly https://semaglutides.org/news/2026/#amgen-maritime-2-extension-opens-enrollment-20262026-09-15T04:35:04Zweekly https://semaglutides.org/news/2026/#fda-warns-research-use-only-peptide-sellers-20262026-09-15T04:34:35Zweekly https://semaglutides.org/news/2026/#foundayo-uk-launch-20262026-09-15T04:34:39Zweekly https://semaglutides.org/news/2026/#lilly-novo-national-advertising-division-copycats-20262026-09-15T04:34:42Zweekly https://semaglutides.org/news/2026/#lilly-novo-lanham-act-503b-compliance-claims-20262026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/#nad-noom-willow-health-drop-compounded-glp-1-claims-20262026-09-15T04:35:03Zweekly https://semaglutides.org/news/2026/#nice-requests-more-information-foundayo-appraisal-20262026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/#zenagamtide-head-to-head-semaglutide-korea-20262026-09-15T04:35:24Zweekly https://semaglutides.org/news/2026/#china-obesity-drug-advertising-workarounds-20262026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/#states-reject-medicaid-glp1-price-deal-20262026-09-15T03:39:39Zweekly https://semaglutides.org/news/2026/#bmj-fact-check-uk-glp-1-death-reports-yellow-card-20262026-09-15T04:35:20Zweekly https://semaglutides.org/news/2026/#tirzepatide-linked-lower-stroke-risk-glp-1-drugs-20262026-09-15T04:35:22Zweekly https://semaglutides.org/news/2026/#medicare-274-negotiated-semaglutide-price-explained-20262026-09-15T04:35:36Zweekly https://semaglutides.org/news/2026/#lilly-breaks-ground-houston-generation-park-20262026-09-15T04:35:25Zweekly https://semaglutides.org/news/2026/#regeneron-olatorepatide-phase-2-obesity-registry-20262026-09-15T04:35:32Zweekly https://semaglutides.org/news/2026/#scholar-rock-apitegromab-regulatory-update-august-20262026-09-15T04:36:19Zweekly https://semaglutides.org/news/2026/#scholar-rock-embraze-lean-mass-data-and-regulatory-update-20262026-09-15T04:35:49Zweekly https://semaglutides.org/news/2026/#structure-accomplish-phase-3-trials-recruiting-20262026-09-15T04:35:56Zweekly https://semaglutides.org/news/2026/#unitedhealthcare-publishes-updated-glp-1-quantity-limits-september-20262026-09-15T04:35:54Zweekly https://semaglutides.org/news/2026/#aon-projects-employer-healthcare-costs-rise-9-5-percent-2027-20262026-09-15T03:39:55Zweekly https://semaglutides.org/news/2026/#pbms-commit-display-trumprx-cash-prices-real-time-benefit-tools-20262026-09-15T03:39:56Zweekly https://semaglutides.org/news/2026/#guardian-documents-brands-scrapping-plus-sizes-glp-1-20262026-09-15T03:40:02Zweekly https://semaglutides.org/news/2026/#glp1-changing-us-healthcare-20262026-09-15T04:35:58Zweekly https://semaglutides.org/news/2026/#gubra-h1-2026-three-partnered-obesity-programs-20262026-09-15T04:36:00Zweekly https://semaglutides.org/news/2026/#meta-analysis-13-243-patients-links-glp-1-20262026-09-15T04:36:08Zweekly https://semaglutides.org/news/2026/#novo-phase-3-lowest-effective-wegovy-pill-dose-20262026-09-15T04:36:17Zweekly https://semaglutides.org/news/2026/#astrazeneca-three-selene-phase-3-trials-amylin-analog-20262026-09-15T03:40:07Zweekly https://semaglutides.org/news/2026/#mississippi-boards-jointly-bar-providers-research-grade-peptides-20262026-09-15T03:40:12Zweekly https://semaglutides.org/news/2026/#novo-presses-fda-semaglutide-ddc-list-20262026-09-15T03:40:15Zweekly https://semaglutides.org/news/2026/#oral-wegovy-outsells-foundayo-first-shared-quarter-20262026-09-15T03:40:28Zweekly https://semaglutides.org/news/2026/#pcos-does-not-blunt-tirzepatide-weight-loss-54-20262026-09-15T03:40:25Zweekly https://semaglutides.org/news/2026/#pharmacy-acquisition-cost-generic-liraglutide-falls-third-six-20262026-09-15T03:40:35Zweekly https://semaglutides.org/news/2026/#va-launches-622-veteran-semaglutide-alcohol-use-disorder-trial-20262026-09-15T03:40:33Zweekly https://semaglutides.org/news/2026/#achieve-5-orforglipron-basal-insulin-results-20262026-09-15T04:36:13Zweekly https://semaglutides.org/news/2026/#amylin-design-debate-lilly-eloralintide-readout-20262026-09-15T04:36:20Zweekly https://semaglutides.org/news/2026/#ftc-first-tracking-pixel-health-data-case-hims-20262026-09-15T04:36:23Zweekly https://semaglutides.org/news/2026/#foundayo-q2-2026-sales2026-09-15T04:36:26Zweekly https://semaglutides.org/news/2026/#nature-reviews-endocrinology-calls-gip-direction-question-seeming-20262026-09-15T04:36:35Zweekly https://semaglutides.org/news/2026/#foodnavigator-new-consumer-data-challenges-glp-1-food-forecasts-20262026-09-15T04:36:53Zweekly https://semaglutides.org/news/2026/#overton-nominated-fda-commissioner-compounding-dockets-20262026-09-15T04:36:49Zweekly https://semaglutides.org/news/2026/#northeastern-asks-whether-ozempic-is-reviving-eating-disorders-20262026-09-15T04:36:39Zweekly https://semaglutides.org/news/2026/#circulation-analysis-select-37-8-drop-inflammation-semaglutide-20262026-09-15T03:40:40Zweekly https://semaglutides.org/news/2026/#canada-warns-illegal-retatrutide-cbp-seizures-jump-20262026-09-15T04:37:06Zweekly https://semaglutides.org/news/2026/#enveda-completes-phase-1-env-308-20262026-09-15T04:37:07Zweekly https://semaglutides.org/news/2026/#fact-checkers-kff-question-drug-price-drop-attribution-20262026-09-15T04:36:55Zweekly https://semaglutides.org/news/2026/#no-lawful-503a-pathway-retatrutide-analysis-20262026-09-15T04:36:45Zweekly https://semaglutides.org/news/2026/#lilly-retatrutide-lawsuits-new-enforcement-playbook-20262026-09-15T04:37:02Zweekly https://semaglutides.org/news/2026/#orforglipron-maintenance-after-injectable-switch-20262026-09-15T04:37:25Zweekly https://semaglutides.org/news/2026/#white-house-claims-largest-drug-price-drop-trumprx-700-million-20262026-09-15T03:40:40Zweekly https://semaglutides.org/news/2026/#axios-analysis-glp-1-competition-behind-drug-price-decline-20262026-09-15T04:37:10Zweekly https://semaglutides.org/news/2026/#novo-132-knockoff-lawsuits-tally-20262026-09-15T04:37:27Zweekly https://semaglutides.org/news/2026/#researchers-name-glp-1-treatment-stigma-distinct-phenomenon-20262026-09-15T04:37:37Zweekly https://semaglutides.org/news/2026/#nestle-plans-products-for-ozempic-face-and-side-effects-20262026-09-15T04:37:24Zweekly https://semaglutides.org/news/2026/#lawsuit-claims-link-between-glp-1-drugs-and-blindness-20262026-09-15T04:37:25Zweekly https://semaglutides.org/news/2026/#novo-canada-ozempic-savings-card-20262026-09-15T04:37:37Zweekly https://semaglutides.org/news/2026/#experiment-documents-weight-loss-drug-users-judged-harshly-20262026-09-15T03:40:46Zweekly https://semaglutides.org/news/2026/#foundayo-eighty-percent-glp1-naive-patients-20262026-09-15T04:37:41Zweekly https://semaglutides.org/news/2026/#novo-moves-preliminary-injunction-lilly-glp-1-ads-20262026-09-15T03:41:03Zweekly https://semaglutides.org/news/2026/#anti-obesity-fourth-class-20262026-09-15T04:37:43Zweekly https://semaglutides.org/news/2026/#lilly-sues-makers-generic-style-mounjaro-zepbound-copies-20262026-09-15T04:37:47Zweekly https://semaglutides.org/news/2026/#survey-1-226-patients-puts-numbers-skin-laxity-20262026-09-15T04:37:44Zweekly https://semaglutides.org/news/2026/#foundayos-label-establishes-no-timing-rules-oral-glp-20262026-09-15T03:41:05Zweekly https://semaglutides.org/news/2026/#kff-prior-authorization-metrics-show-12-18-percent-20262026-09-15T03:40:58Zweekly https://semaglutides.org/news/2026/#retatrutide-black-market-crackdown-20262026-09-15T03:41:12Zweekly https://semaglutides.org/news/2026/#zealand-h1-2026-petrelintide-phase-3-timing-20262026-09-15T03:41:09Zweekly https://semaglutides.org/news/2026/#novo-ceo-claims-90-percent-oral-glp1-share-20262026-09-15T04:38:13Zweekly https://semaglutides.org/news/2026/#lilly-files-lawsuits-retatrutide-gray-market-20262026-09-15T03:06:02Zweekly https://semaglutides.org/news/2026/#anesthesiology-analysis-finds-no-increased-aspiration-risk-preoperative-20262026-09-15T03:41:16Zweekly https://semaglutides.org/news/2026/#prescription-drug-cpi-falls-3-1-percent-steepest-since-1963-20262026-09-15T03:41:27Zweekly https://semaglutides.org/news/2026/#u-s-news-2026-2027-glp-1-telehealth2026-09-15T03:41:34Zweekly https://semaglutides.org/news/2026/#novos-ceo-defends-lawsuit-concedes-lillys-lead-20262026-09-15T04:38:03Zweekly https://semaglutides.org/news/2026/#foundayo-europe-approval-20262026-09-15T04:38:10Zweekly https://semaglutides.org/news/2026/#lateral-septum-cravings-20262026-09-15T04:38:04Zweekly https://semaglutides.org/news/2026/#chrissy-metz-discloses-glp-1-use-joins-ro-20262026-09-15T03:41:44Zweekly https://semaglutides.org/news/2026/#hims-10q-discloses-60-million-ftc-legal-accrual-20262026-09-15T03:41:39Zweekly https://semaglutides.org/news/2026/#mhra-orforglipron-20262026-09-15T03:41:35Zweekly https://semaglutides.org/news/2026/#uk-becomes-country-europe-authorize-orforglipron-20262026-09-15T03:41:38Zweekly https://semaglutides.org/news/2026/#hims-hers-q2-2026-revenue-753-million-gaap2026-09-15T04:38:20Zweekly https://semaglutides.org/news/2026/#antitrust-suit-dismissed-20262026-09-15T03:06:04Zweekly https://semaglutides.org/news/2026/#cms-extends-medicare-glp-1-bridge-through-december-20262026-09-15T03:06:11Zweekly https://semaglutides.org/news/2026/#eli-lilly-48-revenue-growth-raises-2026-guidance2026-09-15T03:06:13Zweekly https://semaglutides.org/news/2026/#lilly-q2-revenue-jumps-48-23-billion-while-20262026-09-15T03:06:21Zweekly https://semaglutides.org/news/2026/#lilly-self-pay-now-zepbound-prescriptions-20262026-09-15T03:06:34Zweekly https://semaglutides.org/news/2026/#mounjaro-zepbound-top-14-8-billion-single-quarter-20262026-09-15T03:06:32Zweekly https://semaglutides.org/news/2026/#foundayo-posts-98-million-partial-quarter-below-expectations-20262026-09-15T03:42:01Zweekly https://semaglutides.org/news/2026/#q2-2026-earnings-comparison2026-09-15T03:42:05Zweekly https://semaglutides.org/news/2026/#retatrutide-filing-plan-20262026-09-15T03:42:04Zweekly https://semaglutides.org/news/2026/#lilly-tirzepatide-revenue-14-9-billion-one-quarter-20262026-09-15T03:42:12Zweekly https://semaglutides.org/news/2026/#novo-q2-2026-raises-outlook2026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/#novo-q2-2026-brand-level-sales-split2026-09-15T03:42:10Zweekly https://semaglutides.org/news/2026/#reimagine-4-miss-20262026-09-15T03:42:15Zweekly https://semaglutides.org/news/2026/#eli-lilly-holds-60-branded-obesity-market-20262026-09-15T03:42:35Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-doses-patients-phase-3-accomplish-program-20262026-09-15T03:42:35Zweekly https://semaglutides.org/news/2026/#ziltivekimab-fails-zeus-heart-trial-erasing-30-billion-20262026-09-15T03:06:43Zweekly https://semaglutides.org/news/2026/#zeus-trial-fails-20262026-09-15T03:42:37Zweekly https://semaglutides.org/news/2026/#section-232-pharmaceutical-tariffs-take-effect-17-named-20262026-09-15T03:42:51Zweekly https://semaglutides.org/news/2026/#503b-comment-closes-20262026-09-15T03:42:49Zweekly https://semaglutides.org/news/2026/#ftc-utah-los-angeles-county-sue-hims-hers-20262026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/#oral-semaglutide-reduces-heavy-drinking-treatment-seeking-trial-20262026-09-15T03:42:49Zweekly https://semaglutides.org/news/2026/#japanese-cohort-finds-2-5-mg-5-mg-20262026-09-15T03:43:05Zweekly https://semaglutides.org/news/2026/#rest-trial-protocol-published-formalizing-taper-question-20262026-09-15T03:43:05Zweekly https://semaglutides.org/news/2026/#novo-seeks-injunction-on-lilly-ads-20262026-09-15T03:43:03Zweekly https://semaglutides.org/news/2026/#two-brain-regions-found-explain-gip-paradox-20262026-09-15T03:43:25Zweekly https://semaglutides.org/news/2026/#triumph-2-3-results-20262026-09-15T03:06:54Zweekly https://semaglutides.org/news/2026/#australia-adds-naion-all-glp-1-product-information-20262026-09-15T03:43:37Zweekly https://semaglutides.org/news/2026/#fda-advisory-committee-recommends-six-peptides-503a-bulks-20262026-09-15T03:43:24Zweekly https://semaglutides.org/news/2026/#lilly-retatrutide-ready-file-targeting-obesity-sleep-apnea-20262026-09-15T03:43:34Zweekly https://semaglutides.org/news/2026/#bmj-study-finds-glp-1-drugs-raise-risk-20262026-09-15T03:43:32Zweekly https://semaglutides.org/news/2026/#novo-challenges-lilly-ads-20262026-09-15T03:07:04Zweekly https://semaglutides.org/news/2026/#president-phased-tariffs-imported-generic-drugs-20262026-09-15T03:07:07Zweekly https://semaglutides.org/news/2026/#ec-approves-wegovy-pill-20262026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/#goodrx-114-million-americans-no-commercial-coverage-zepbound-20262026-09-15T03:43:37Zweekly https://semaglutides.org/news/2026/#largest-tirzepatide-faers-study-finds-medication-errors-top-20262026-09-15T03:43:57Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-accomplish-phase-3-program-aleniglipron-20262026-09-15T03:43:55Zweekly https://semaglutides.org/news/2026/#meta-analysis-finds-no-clear-rise-birth-defects-20262026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/#bmj-network-meta-analysis-biggest-fat-loss-biggest-20262026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/#survey-finds-glp-1s-now-11-4-employer-20262026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/#gallup-11-adults-now-take-glp-1-weight-20262026-09-15T03:07:15Zweekly https://semaglutides.org/news/2026/#masshealth-stops-covering-glp-1s-prescribed-only-weight-20262026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/#audit-finds-compounded-glp-1-market-still-operating-20262026-09-15T03:44:08Zweekly https://semaglutides.org/news/2026/#medicare-bridge-live-20262026-09-15T03:07:29Zweekly https://semaglutides.org/news/2026/#medicare-glp-1-bridge-publishing-explicit-bmi-eligibility-20262026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/#massachusetts-gic-ends-obesity-only-glp-1-coverage-20262026-09-15T03:44:26Zweekly https://semaglutides.org/news/2026/#apollo-care-recalls-roughly-162-000-vials-compounded-20262026-09-15T03:44:24Zweekly https://semaglutides.org/news/2026/#jama-health-forum-secret-shopper-study-finds-compounded-20262026-09-15T03:44:37Zweekly https://semaglutides.org/news/2026/#summary-judgment-briefing-completes-mdl-3094-20262026-09-15T03:44:34Zweekly https://semaglutides.org/news/2026/#nationwide-cohort-208-155-post-bariatric-patients-finds-20262026-09-15T03:44:32Zweekly https://semaglutides.org/news/2026/#wegovy-label-consolidates-injection-tablet-one-prescribing-information-2026-22026-09-15T03:44:45Zweekly https://semaglutides.org/news/2026/#health-canada-approves-generic-semaglutide-weight-loss-20262026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/#astrazeneca-opens-embold-phase-3-master-protocol-elecoglipron-20262026-09-15T03:44:54Zweekly https://semaglutides.org/news/2026/#fda-accepts-sandoz-applications-generic-tirzepatide-20262026-09-15T03:44:54Zweekly https://semaglutides.org/news/2026/#chmp-recommends-adding-surpass-cvot-results-eu-mounjaro-20262026-09-15T03:45:08Zweekly https://semaglutides.org/news/2026/#cms-data-shows-liraglutide-brand-spending-collapsed-generic-20262026-09-15T03:45:12Zweekly https://semaglutides.org/news/2026/#pwc-finds-one-five-households-now-includes-glp-20262026-09-15T03:07:41Zweekly https://semaglutides.org/news/2026/#college-physicians-issues-living-guideline-obesity-pharmacotherapy-20262026-09-15T03:45:15Zweekly https://semaglutides.org/news/2026/#fda-sends-25-letters-telehealth-companies-compounded-weight-20262026-09-15T03:45:11Zweekly https://semaglutides.org/news/2026/#fda-issues-25-warning-letters-telehealth-companies-compounded-20262026-09-15T03:45:18Zweekly https://semaglutides.org/news/2026/#fda-publishes-list-unlawful-compounded-drug-marketing-claims-20262026-09-15T03:45:17Zweekly https://semaglutides.org/news/2026/#fda-updates-guidance-page-telehealth-companies-promoting-compounded-20262026-09-15T03:45:30Zweekly https://semaglutides.org/news/2026/#bcbs-federal-employee-program-approves-zepbound-policy-requiring-20262026-09-15T03:45:42Zweekly https://semaglutides.org/news/2026/#mhra-approves-wegovy-tablet-european-20262026-09-15T03:45:37Zweekly https://semaglutides.org/news/2026/#surveys-show-employers-pulling-back-glp-1-coverage-20262026-09-15T03:45:42Zweekly https://semaglutides.org/news/2026/#mhra-wegovy-pill-approval-20262026-09-15T03:45:43Zweekly https://semaglutides.org/news/2026/#shaquille-oneal-he-takes-zepbound-sleep-apnea-20262026-09-15T03:45:46Zweekly https://semaglutides.org/news/2026/#wegovy-pill-new-patients-20262026-09-15T03:45:59Zweekly https://semaglutides.org/news/2026/#achieve-3-lillys-oral-pill-beats-oral-semaglutide-20262026-09-15T03:46:03Zweekly https://semaglutides.org/news/2026/#astrazenecas-elecoglipron-moves-phase-3-11-8-weight-20262026-09-15T03:46:18Zweekly https://semaglutides.org/news/2026/#retatrutide-black-market-cbs-20262026-09-15T03:46:12Zweekly https://semaglutides.org/news/2026/#faers-comparison-puts-tirzepatides-optic-neuropathy-signal-far-20262026-09-15T03:46:14Zweekly https://semaglutides.org/news/2026/#fda-issues-warning-letters-altru-telehealth-fitish-others-20262026-09-15T03:46:14Zweekly https://semaglutides.org/news/2026/#wegovy-pill-3m-scripts-20262026-09-15T03:07:51Zweekly https://semaglutides.org/news/2026/#annals-oncology-glp-1-use-tied-41-percent-20262026-09-15T03:46:29Zweekly https://semaglutides.org/news/2026/#cagrisema-reimagine-ada-20262026-09-15T03:46:34Zweekly https://semaglutides.org/news/2026/#novo-nordisk-presents-cagrisema-reimagine-zenagamtide-data-ada-20262026-09-15T03:46:45Zweekly https://semaglutides.org/news/2026/#survodutide-phase-3-data-published-nejm-show-34-20262026-09-15T03:46:48Zweekly https://semaglutides.org/news/2026/#pfizer-details-monthly-berobenatide-data-plans-10-phase-20262026-09-15T03:46:42Zweekly https://semaglutides.org/news/2026/#retatrutide-cuts-sleep-apnea-severity-60-percent-triumph-20262026-09-15T03:46:45Zweekly https://semaglutides.org/news/2026/#retatrutide-ada-full-data-20262026-09-15T03:47:00Zweekly https://semaglutides.org/news/2026/#ada-2026-opens2026-09-15T03:47:04Zweekly https://semaglutides.org/news/2026/#consensus-issues-practical-guidelines-glp-1-use-type-20262026-09-15T03:47:08Zweekly https://semaglutides.org/news/2026/#large-cohort-quantifies-motility-risk-glp-1-drugs-20262026-09-15T03:47:14Zweekly https://semaglutides.org/news/2026/#cigna-drops-glp-1-coverage-own-employees-20262026-09-15T03:47:12Zweekly https://semaglutides.org/news/2026/#phase-1b-trial-separates-what-gip-glp-1-20262026-09-15T03:47:20Zweekly https://semaglutides.org/news/2026/#science-held-glp-1-vision-loss-mdl-20262026-09-15T03:47:32Zweekly https://semaglutides.org/news/2026/#cvs-caremark-lifts-market-block-foundayo-20262026-09-15T03:47:34Zweekly https://semaglutides.org/news/2026/#eli-lilly-registers-pre-approval-expanded-access-program-20262026-09-15T03:47:38Zweekly https://semaglutides.org/news/2026/#cagrisema-decision-date-20262026-09-15T03:47:47Zweekly https://semaglutides.org/news/2026/#surpass-early-two-results-favor-starting-tirzepatide-early-20262026-09-15T03:47:41Zweekly https://semaglutides.org/news/2026/#fda-count-reaches-990-adverse-event-compounded-semaglutide-20262026-09-15T03:47:46Zweekly https://semaglutides.org/news/2026/#cvs-restores-zepbound-announcement-20262026-09-15T03:07:45Zweekly https://semaglutides.org/news/2026/#all-three-major-pbms-agree-cover-foundayo-20262026-09-15T03:48:03Zweekly https://semaglutides.org/news/2026/#anvisa-approves-brazils-generic-semaglutide-pen-20262026-09-15T03:47:59Zweekly https://semaglutides.org/news/2026/#bari-step-semaglutide-rescues-poor-weight-loss-bariatric-20262026-09-15T03:08:10Zweekly https://semaglutides.org/news/2026/#narb-upholds-clinically-proven-claims-must-substantiated-regardless-20262026-09-15T03:48:03Zweekly https://semaglutides.org/news/2026/#retatrutide-triumph-1-20262026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/#triumph-1-topline-retatrutide-reaches-28-3-weight-20262026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/#chmp-wegovy-pill-opinion-20262026-09-15T03:48:10Zweekly https://semaglutides.org/news/2026/#fda-1-700-adverse-events-tied-compounded-glp-20262026-09-15T03:48:13Zweekly https://semaglutides.org/news/2026/#hims-offering-generic-semaglutide-canada-20262026-09-15T03:48:18Zweekly https://semaglutides.org/news/2026/#narb-affirms-nad-tru-niagen-matter-20262026-09-15T03:48:37Zweekly https://semaglutides.org/news/2026/#plos-medicine-pooled-analysis-puts-naion-risk-absolute-20262026-09-15T03:48:32Zweekly https://semaglutides.org/news/2026/#eli-lilly-files-roadmap-brief-seeking-summary-judgment-20262026-09-15T03:48:34Zweekly https://semaglutides.org/news/2026/#academy-ophthalmology-tirzepatides-naion-risk-studied-20262026-09-15T03:48:48Zweekly https://semaglutides.org/news/2026/#apotex-generic-semaglutide-injection-canada-20262026-09-15T03:48:45Zweekly https://semaglutides.org/news/2026/#attain-maintain-tests-switching-injection-oral-glp-1-20262026-09-15T03:08:08Zweekly https://semaglutides.org/news/2026/#eco-2026-adding-glp-1-behavioral-treatment-cuts2026-09-15T03:48:48Zweekly https://semaglutides.org/news/2026/#surmount-maintain-lancet-20262026-09-15T03:08:20Zweekly https://semaglutides.org/news/2026/#detailed-attain-maintain-results-published-nature-medicine-20262026-09-15T03:49:16Zweekly https://semaglutides.org/news/2026/#lilly-marks-150-ceremony-indianapolis-20262026-09-15T03:49:17Zweekly https://semaglutides.org/news/2026/#lilly-foundayo-lower-dose-zepbound-maintain-weight-loss-20262026-09-15T03:49:10Zweekly https://semaglutides.org/news/2026/#surpass-cvot-kidney-analysis-23-lower-rate-major-20262026-09-15T03:49:23Zweekly https://semaglutides.org/news/2026/#medicare-glp1-bridge-announced-20262026-09-15T03:08:17Zweekly https://semaglutides.org/news/2026/#mounjaro-passes-keytruda-worlds-best-selling-drug-20262026-09-15T03:08:31Zweekly https://semaglutides.org/news/2026/#business-group-health-finds-67-large-employers-cover-20262026-09-15T03:49:16Zweekly https://semaglutides.org/news/2026/#lilly-adds-4-5-billion-indiana-where-tirzepatide-20262026-09-15T03:49:17Zweekly https://semaglutides.org/news/2026/#q1-2026-wegovy-pill-posts-dkk-2-262026-09-15T03:49:44Zweekly https://semaglutides.org/news/2026/#ozempic-tablets-available-20262026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/#ozempic-pill-united-states-type-2-diabetes-20262026-09-15T03:49:47Zweekly https://semaglutides.org/news/2026/#rybelsus-relaunches-reformulated-ozempic-pill-20262026-09-15T03:49:45Zweekly https://semaglutides.org/news/2026/#apotex-wins-canadian-approval-apo-semaglutide-20262026-09-15T03:49:42Zweekly https://semaglutides.org/news/2026/#balance-model-delayed-20262026-09-15T03:49:54Zweekly https://semaglutides.org/news/2026/#colorado-makes-zepbound-only-weight-loss-glp-1-20262026-09-15T03:49:49Zweekly https://semaglutides.org/news/2026/#health-canada-approves-second-generic-semaglutide-apotex-20262026-09-15T03:50:07Zweekly https://semaglutides.org/news/2026/#novo-nordisk-date-ozempic-tablets-20262026-09-15T03:50:11Zweekly https://semaglutides.org/news/2026/#503b-bulks-list-proposal-publishes-federal-register-20262026-09-15T03:50:18Zweekly https://semaglutides.org/news/2026/#fda-503b-bulk-proposal-20262026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/#iu-study-lilly-supports-47-520-indiana-jobs-20262026-09-15T03:50:23Zweekly https://semaglutides.org/news/2026/#ozempic-prescribing-information-revised-still-no-naion-warning-20262026-09-15T03:50:14Zweekly https://semaglutides.org/news/2026/#fda-proposes-exclude-semaglutide-tirzepatide-liraglutide-503b-bulks-20262026-09-15T03:08:42Zweekly https://semaglutides.org/news/2026/#lilly-60-1-incretin-market-share-20262026-09-15T03:08:47Zweekly https://semaglutides.org/news/2026/#nih-randomized-win-glp-1-drug-alcohol-use-20262026-09-15T03:08:53Zweekly https://semaglutides.org/news/2026/#eating-disorder-clinicians-warn-cultural-swing-back-thin-20262026-09-15T03:50:27Zweekly https://semaglutides.org/news/2026/#lancet-trial-semaglutide-cuts-heavy-drinking-alcohol-use-20262026-09-15T03:50:35Zweekly https://semaglutides.org/news/2026/#lilly-q1-2026-detail-20262026-09-15T03:50:41Zweekly https://semaglutides.org/news/2026/#mdl-3094-sets-expert-evidence-hearing-will-decide-20262026-09-15T03:50:50Zweekly https://semaglutides.org/news/2026/#summary-judgment-briefing-filed-mdl-3094-warnings-adequacy-20262026-09-15T03:50:51Zweekly https://semaglutides.org/news/2026/#systematic-review-quantifies-incretin-contraceptive-interaction-20262026-09-15T03:50:53Zweekly https://semaglutides.org/news/2026/#court-rules-lilly-v-empower-clinic-services-compounded-20262026-09-15T03:50:51Zweekly https://semaglutides.org/news/2026/#roche-zealand-pharma-commit-petrelintide-phase-3-20262026-09-15T03:51:08Zweekly https://semaglutides.org/news/2026/#health-canada-approves-generic-semaglutide-g7-20262026-09-15T03:08:58Zweekly https://semaglutides.org/news/2026/#mdl-3094-daubert-deadline-20262026-09-15T03:51:10Zweekly https://semaglutides.org/news/2026/#meta-analysis-49-395-pregnancies-finds-no-clear-20262026-09-15T03:51:19Zweekly https://semaglutides.org/news/2026/#boehringer-ingelheims-survodutide-hits-16-6-weight-loss-20262026-09-15T03:51:21Zweekly https://semaglutides.org/news/2026/#hims-hers-adds-zepbound-zepbound-kwikpen-foundayo-via-20262026-09-15T03:51:26Zweekly https://semaglutides.org/news/2026/#goodrx-npr-document-12-million-people-losing-zepbound-20262026-09-15T03:51:26Zweekly https://semaglutides.org/news/2026/#lean-prep-protocol-published-randomized-trial-lifting-weights-20262026-09-15T03:51:36Zweekly https://semaglutides.org/news/2026/#cms-shelves-balance-model-medicare-part-d-extends-20262026-09-15T03:09:07Zweekly https://semaglutides.org/news/2026/#amazon-nationwide-glp-1-program-through-one-medical-20262026-09-15T03:51:44Zweekly https://semaglutides.org/news/2026/#iqvia-sizes-global-obesity-medicines-market-66-billion-20262026-09-15T03:51:49Zweekly https://semaglutides.org/news/2026/#lilly-agrees-acquire-kelonia-therapeutics-deal-worth-7-20262026-09-15T03:51:47Zweekly https://semaglutides.org/news/2026/#achieve-4-results-20262026-09-15T03:09:09Zweekly https://semaglutides.org/news/2026/#cms-proposes-extending-electronic-prior-authorization-standards-drugs-20262026-09-15T03:52:01Zweekly https://semaglutides.org/news/2026/#fda-asks-lilly-heart-liver-data-newly-approved-20262026-09-15T03:51:57Zweekly https://semaglutides.org/news/2026/#fda-asks-more-foundayo-safety-data-20262026-09-15T03:52:07Zweekly https://semaglutides.org/news/2026/#apotex-wins-fda-tentative-approval-generic-semaglutide-20262026-09-15T03:52:12Zweekly https://semaglutides.org/news/2026/#foundayo-goes-sale-united-states-20262026-09-15T03:09:13Zweekly https://semaglutides.org/news/2026/#foundayo-reaches-pharmacies-20262026-09-15T03:52:20Zweekly https://semaglutides.org/news/2026/#georgetown-study-finds-glp-1-weight-loss-draws-20262026-09-15T03:52:18Zweekly https://semaglutides.org/news/2026/#lilly-foundayo-oral-glp-1-20262026-09-15T03:52:26Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-prorx-llc-sterility-quality-deficiencies-20262026-09-15T03:52:34Zweekly https://semaglutides.org/news/2026/#wegovy-hd-goes-sale-nationwide-399-self-pay-20262026-09-15T03:52:37Zweekly https://semaglutides.org/news/2026/#foundayo-launch-20262026-09-15T03:09:18Zweekly https://semaglutides.org/news/2026/#cms-adds-foundayo-medicare-glp-1-bridge-clarifies-20262026-09-15T03:52:39Zweekly https://semaglutides.org/news/2026/#imputed-placebo-analysis-estimates-28-mace-reduction-tirzepatide-20262026-09-15T03:52:45Zweekly https://semaglutides.org/news/2026/#section-232-pharmaceutical-tariff-proclamation-sets-lillys-rate-20262026-09-15T03:09:25Zweekly https://semaglutides.org/news/2026/#foundayo-approval-20262026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/#fda-clarifies-compounding-rules-glp-1-supply-stabilizes-20262026-09-15T03:09:32Zweekly https://semaglutides.org/news/2026/#fda-clarifies-essentially-copy-rule-four-prescription-threshold-20262026-09-15T03:09:35Zweekly https://semaglutides.org/news/2026/#fda-sets-four-prescriptions-yardstick-copy-compounding-20262026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/#fda-spells-what-counts-essentially-copy-compounded-glp-20262026-09-15T03:09:47Zweekly https://semaglutides.org/news/2026/#foundayo-orforglipron-approval-creates-biggest-comparison-opportunity-20262026-09-15T03:09:59Zweekly https://semaglutides.org/news/2026/#fda-restates-tirzepatide-neither-shortage-list-nor-503b-20262026-09-15T03:52:45Zweekly https://semaglutides.org/news/2026/#foundayo-fastest-approval-20262026-09-15T03:52:54Zweekly https://semaglutides.org/news/2026/#nhs-england-moves-tirzepatide-prescribing-gp-contract-20262026-09-15T03:53:07Zweekly https://semaglutides.org/news/2026/#tos-oma-oac-give-continuing-medication-during-maintenance-20262026-09-15T03:10:02Zweekly https://semaglutides.org/news/2026/#first-wave-loe-markets-20262026-09-15T03:53:08Zweekly https://semaglutides.org/news/2026/#part-d-glp1-coverage-requirement-20262026-09-15T03:53:12Zweekly https://semaglutides.org/news/2026/#swedish-national-cohort-finds-semaglutide-linked-lower-risk-20262026-09-15T03:53:10Zweekly https://semaglutides.org/news/2026/#wegovy-hd-launch-20262026-09-15T03:53:16Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-gram-peptides-citing-tirzepatide-20262026-09-15T03:53:19Zweekly https://semaglutides.org/news/2026/#fda-warns-research-peptide-sellers-gram-peptides-prime-20262026-09-15T03:53:32Zweekly https://semaglutides.org/news/2026/#lilly-agrees-acquire-centessa-pharmaceuticals-6-3-billion-20262026-09-15T03:53:41Zweekly https://semaglutides.org/news/2026/#wegovy-subscription-20262026-09-15T03:53:42Zweekly https://semaglutides.org/news/2026/#opm-carrier-letter-2026-07-sets-plan-20272026-09-15T03:53:40Zweekly https://semaglutides.org/news/2026/#surpass-cvot-post-hoc-finds-broad-cardiorenal-benefit-20262026-09-15T03:53:50Zweekly https://semaglutides.org/news/2026/#destination-xl-blames-glp-1s-size-volatility-apparel-20262026-09-15T03:53:46Zweekly https://semaglutides.org/news/2026/#meta-analysis-puts-number-what-resistance-training-changes-20262026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/#india-price-war-20262026-09-15T03:54:08Zweekly https://semaglutides.org/news/2026/#dozen-indian-generic-semaglutide-brands-one-20262026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/#cnbc-quantifies-glp-1-hit-restaurant-dinner-traffic-20262026-09-15T03:54:06Zweekly https://semaglutides.org/news/2026/#china-brazil-patent-expiry-20262026-09-15T03:10:21Zweekly https://semaglutides.org/news/2026/#india-patent-expiry-20262026-09-15T03:10:15Zweekly https://semaglutides.org/news/2026/#wegovy-hd-approval-20262026-09-15T03:10:38Zweekly https://semaglutides.org/news/2026/#imcivree-becomes-approved-treatment-acquired-hypothalamic-obesity-20262026-09-15T03:10:31Zweekly https://semaglutides.org/news/2026/#dysesthesia-enters-semaglutide-label-dose-related-side-effect-20262026-09-15T03:54:11Zweekly https://semaglutides.org/news/2026/#adpd-2026-evoke-full-data2026-09-15T03:54:15Zweekly https://semaglutides.org/news/2026/#lancet-psychiatry-semaglutide-linked-42-percent-lower-risk-20262026-09-15T03:54:11Zweekly https://semaglutides.org/news/2026/#transcend-t2d-1-results-20262026-09-15T03:54:22Zweekly https://semaglutides.org/news/2026/#wegovy-hd-approval-creates-dose-upgrade-query-cluster-20262026-09-15T03:54:46Zweekly https://semaglutides.org/news/2026/#cnpv-program-glp1-20262026-09-15T03:54:42Zweekly https://semaglutides.org/news/2026/#indiana-commits-1-billion-life-sciences-agriculture-20262026-09-15T03:54:37Zweekly https://semaglutides.org/news/2026/#zepbound-kwikpen-self-pay-pricing-reaches-pharmacies-nationwide-20262026-09-15T03:10:36Zweekly https://semaglutides.org/news/2026/#oculus-trial-stops-early-residual-stomach-contents-rise-20262026-09-15T03:54:42Zweekly https://semaglutides.org/news/2026/#cleveland-clinic-finds-people-who-stop-glp-1s-20262026-09-15T03:54:46Zweekly https://semaglutides.org/news/2026/#tirzepatide-b12-impurity-warning-20262026-09-15T03:54:54Zweekly https://semaglutides.org/news/2026/#novo-holdings-assets-34-2025-20262026-09-15T03:55:06Zweekly https://semaglutides.org/news/2026/#fda-retires-faers-adverse-event-monitoring-system-20262026-09-15T03:55:07Zweekly https://semaglutides.org/news/2026/#novo-hims-settlement-20262026-09-15T03:10:37Zweekly https://semaglutides.org/news/2026/#cms-issues-balance-implementation-details-naming-zepbound-mounjaro-20262026-09-15T03:55:10Zweekly https://semaglutides.org/news/2026/#eli-lilly-employer-connect-selling-zepbound-employers-449-20262026-09-15T03:10:43Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-pade-20262026-09-15T03:10:49Zweekly https://semaglutides.org/news/2026/#meta-regression-maps-shape-weight-regain-stopping-glp-20262026-09-15T03:10:57Zweekly https://semaglutides.org/news/2026/#fda-30-warning-letters-20262026-09-15T03:11:06Zweekly https://semaglutides.org/news/2026/#cms-publishes-medicare-glp-1-bridge-frequently-asked-20262026-09-15T03:55:20Zweekly https://semaglutides.org/news/2026/#march-2026-compounding-turning-point2026-09-15T03:55:19Zweekly https://semaglutides.org/news/2026/#us-label-no-naion-warning-20262026-09-15T03:55:24Zweekly https://semaglutides.org/news/2026/#prime-therapeutics-claims-data-show-real-world-one-20262026-09-15T03:55:33Zweekly https://semaglutides.org/news/2026/#two-large-claims-studies-disagree-tirzepatide-versus-semaglutide-20262026-09-15T03:55:40Zweekly https://semaglutides.org/news/2026/#achieve-3-lancet-20262026-09-15T03:55:39Zweekly https://semaglutides.org/news/2026/#massachusetts-group-insurance-commission-votes-eliminate-glp-1-20262026-09-15T03:55:44Zweekly https://semaglutides.org/news/2026/#general-mills-ceo-anti-obesity-drugs-will-have-20262026-09-15T03:55:53Zweekly https://semaglutides.org/news/2026/#zepbound-label-drops-suicidality-warning-adds-intestinal-obstruction-20262026-09-15T03:55:56Zweekly https://semaglutides.org/news/2026/#novo-list-price-cut-20262026-09-15T03:11:07Zweekly https://semaglutides.org/news/2026/#2027-list-price-cut-guarantees-undated-cost-pages-20262026-09-15T03:56:05Zweekly https://semaglutides.org/news/2026/#falsified-mounjaro-kwikpen-15-mg-pens-found-uk-20262026-09-15T03:56:04Zweekly https://semaglutides.org/news/2026/#fda-approves-two-generic-saxenda-products-same-20262026-09-15T03:56:11Zweekly https://semaglutides.org/news/2026/#mounjaro-approved-children-10-older-type-2-diabetes-20262026-09-15T03:56:09Zweekly https://semaglutides.org/news/2026/#novo-nordisks-licensed-triple-agonist-ubt251-shows-19-20262026-09-15T03:56:20Zweekly https://semaglutides.org/news/2026/#reduced-frequency-dosing-case-series-published-obesity-20262026-09-15T03:56:32Zweekly https://semaglutides.org/news/2026/#cagrisema-loses-tirzepatide-redefine-4-novo-nordisk-shares-20262026-09-15T03:11:05Zweekly https://semaglutides.org/news/2026/#redefine-4-miss-20262026-09-15T03:11:15Zweekly https://semaglutides.org/news/2026/#lilly-zepbound-kwikpen-same-self-pay-price-vial-20262026-09-15T03:11:19Zweekly https://semaglutides.org/news/2026/#fda-approves-four-dose-zepbound-kwikpen-putting-tirzepatide-20262026-09-15T03:56:35Zweekly https://semaglutides.org/news/2026/#lilly-calls-zepbound-prescribed-weight-management-medication-2025-20262026-09-15T03:56:34Zweekly https://semaglutides.org/news/2026/#zepbound-multi-dose-kwikpen-becomes-available-20262026-09-15T03:56:40Zweekly https://semaglutides.org/news/2026/#fda-issues-30-warning-letters-telehealth-companies-marketing-20262026-09-15T03:11:24Zweekly https://semaglutides.org/news/2026/#fda-warns-medvi-misbranded-compounded-glp-1-products-20262026-09-15T03:56:41Zweekly https://semaglutides.org/news/2026/#circuit-upholds-health-plans-weight-loss-drug-exclusion-20262026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/#analysis-finds-bariatric-surgery-volume-13-glp-1-20262026-09-15T03:56:44Zweekly https://semaglutides.org/news/2026/#european-commission-approves-wegovy-7-2-mg-20262026-09-15T03:56:56Zweekly https://semaglutides.org/news/2026/#largest-naion-study-date-va-cohort-finds-double-20262026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/#novo-sues-hims-20262026-09-15T03:11:38Zweekly https://semaglutides.org/news/2026/#glp1-super-bowl-20262026-09-15T03:11:56Zweekly https://semaglutides.org/news/2026/#fda-restricts-glp1-compounding-20262026-09-15T03:11:48Zweekly https://semaglutides.org/news/2026/#fda-threatens-seizure-injunction-compounded-glp-1-marketing-20262026-09-15T03:11:52Zweekly https://semaglutides.org/news/2026/#trumprx-launches-20262026-09-15T03:12:06Zweekly https://semaglutides.org/news/2026/#hims-49-pill-launch-20262026-09-15T03:12:15Zweekly https://semaglutides.org/news/2026/#trumprx-gov-glp-1-coupons-20262026-09-15T03:12:13Zweekly https://semaglutides.org/news/2026/#lilly-q4-2025-results2026-09-15T03:57:00Zweekly https://semaglutides.org/news/2026/#wegovy-pill-economics-20262026-09-15T03:57:06Zweekly https://semaglutides.org/news/2026/#mhra-naion-dsu-20262026-09-15T03:57:10Zweekly https://semaglutides.org/news/2026/#trumprx-gov-zepbound-mounjaro-listings-20262026-09-15T03:57:14Zweekly https://semaglutides.org/news/2026/#lilly-2025-results-mounjaro-23-0-billion-zepbound-20262026-09-15T03:12:19Zweekly https://semaglutides.org/news/2026/#lilly-2025-revenue-65-2-billion-45-guides-20262026-09-15T03:12:25Zweekly https://semaglutides.org/news/2026/#novo-shares-plunge-feb-20262026-09-15T03:12:29Zweekly https://semaglutides.org/news/2026/#fda-approves-rybelsus-ozempic-tablets-name-change-orphaning-20262026-09-15T03:57:22Zweekly https://semaglutides.org/news/2026/#lilly-novo-nordisk-issue-sharply-diverging-2026-guidance2026-09-15T03:57:21Zweekly https://semaglutides.org/news/2026/#lilly-q4-2025-detail-20262026-09-15T03:57:26Zweekly https://semaglutides.org/news/2026/#ozempic-pill-introduced-20262026-09-15T03:57:41Zweekly https://semaglutides.org/news/2026/#full-2025-results-sales-dkk-309-1-billion-20262026-09-15T03:12:38Zweekly https://semaglutides.org/news/2026/#novo-2026-guidance-shock2026-09-15T03:12:45Zweekly https://semaglutides.org/news/2026/#judge-dismisses-eli-lillys-case-against-willow-health-20262026-09-15T03:57:37Zweekly https://semaglutides.org/news/2026/#pfizers-monthly-glp-1-hits-phase-2b-endpoint-20262026-09-15T03:57:48Zweekly https://semaglutides.org/news/2026/#analysts-trim-obesity-drug-market-forecasts-30-20262026-09-15T03:12:46Zweekly https://semaglutides.org/news/2026/#reimagine-2-results-20262026-09-15T03:57:52Zweekly https://semaglutides.org/news/2026/#claims-analysis-shows-tirzepatide-displacing-time-cpap-20262026-09-15T03:57:48Zweekly https://semaglutides.org/news/2026/#rest-trial-recruiting-randomized-test-tapering-versus-stopping-20262026-09-15T03:12:48Zweekly https://semaglutides.org/news/2026/#zepbounds-suicidal-ideation-warning-removed-severe-gastrointestinal-section-20262026-09-15T03:12:59Zweekly https://semaglutides.org/news/2026/#second-third-generic-saxenda-products-reach-pharmacies-20262026-09-15T03:58:01Zweekly https://semaglutides.org/news/2026/#suicidal-behavior-ideation-section-removed-saxenda-label-20262026-09-15T03:58:05Zweekly https://semaglutides.org/news/2026/#truveta-records-show-tirzepatide-outperforming-semaglutide-outside-trials-20262026-09-15T03:58:10Zweekly https://semaglutides.org/news/2026/#astrazeneca-signs-obesity-deal-chinas-cspc-worth-18-20262026-09-15T03:58:16Zweekly https://semaglutides.org/news/2026/#eu-declines-separate-hfpef-indication-tirzepatide-adds-summit-20262026-09-15T03:58:15Zweekly https://semaglutides.org/news/2026/#rybelsus-becomes-ozempic-tablets-20262026-09-15T03:58:24Zweekly https://semaglutides.org/news/2026/#lilly-pennsylvania-3-5b-20262026-09-15T03:58:28Zweekly https://semaglutides.org/news/2026/#mhra-strengthens-pancreatitis-warnings-entire-glp-1-class-20262026-09-15T03:13:03Zweekly https://semaglutides.org/news/2026/#chmp-refuses-eu-heart-failure-indication-accepts-summit-20262026-09-15T03:58:33Zweekly https://semaglutides.org/news/2026/#kff-medicare-advantage-insurers-denied-4-1-million-20262026-09-15T03:58:41Zweekly https://semaglutides.org/news/2026/#reuters-novo-outspent-lilly-two-one-glp-1-20262026-09-15T03:58:40Zweekly https://semaglutides.org/news/2026/#ira-round-three-selection-20262026-09-15T03:13:07Zweekly https://semaglutides.org/news/2026/#roches-enicepatide-posts-22-5-placebo-adjusted-weight-20262026-09-15T03:58:50Zweekly https://semaglutides.org/news/2026/#fda-approves-mounjaro-kwikpen-zepbound-kwikpen-20262026-09-15T03:13:16Zweekly https://semaglutides.org/news/2026/#surmount-maintain-completes-testing-step-dose-instead-stopping-20262026-09-15T03:58:51Zweekly https://semaglutides.org/news/2026/#kff-counts-13-state-medicaid-programs-covering-glp-20262026-09-15T03:13:14Zweekly https://semaglutides.org/news/2026/#jefferies-estimates-glp-1s-could-save-airlines-580-20262026-09-15T03:59:00Zweekly https://semaglutides.org/news/2026/#compounder-antitrust-suit-20262026-09-15T03:59:07Zweekly https://semaglutides.org/news/2026/#fda-asks-drugmakers-drop-suicidal-thoughts-warning-glp-20262026-09-15T03:13:20Zweekly https://semaglutides.org/news/2026/#obesity-association-publishes-2026-pharmacologic-treatment-standards-ranking2026-09-15T03:13:40Zweekly https://semaglutides.org/news/2026/#fda-asks-removal-suicidal-ideation-warning-stranding-generation-20262026-09-15T03:59:13Zweekly https://semaglutides.org/news/2026/#novo-nordisks-wegovy-pill-ad-debuts-during-golden-20262026-09-15T03:59:10Zweekly https://semaglutides.org/news/2026/#taltz-zepbound-psa-topline-20262026-09-15T03:59:17Zweekly https://semaglutides.org/news/2026/#bmj-meta-analysis-quantifies-weight-regain-stopping-obesity-20262026-09-15T03:59:21Zweekly https://semaglutides.org/news/2026/#fda-approves-multi-dose-tirzepatide-vials-both-brands-20262026-09-15T03:59:38Zweekly https://semaglutides.org/news/2026/#wegovy-pill-launch-20262026-09-15T03:13:32Zweekly https://semaglutides.org/news/2026/#wegovy-pill-oral-glp-1-approved-obesity-20262026-09-15T03:13:46Zweekly https://semaglutides.org/news/2026/#novo-nordisks-canadian-data-exclusivity-semaglutide-expires-20262026-09-15T03:13:47Zweekly https://semaglutides.org/news/2026/#canada-patent-expiry-20262026-09-15T03:59:39Zweekly https://semaglutides.org/news/2026/#michigan-medicaid-restricts-glp-1-obesity-coverage-bmi-20262026-09-15T03:13:49Zweekly https://semaglutides.org/news/2026/#semaglutide-exclusivity-expiring-outside-united-states-20262026-09-15T03:13:56Zweekly https://semaglutides.org/news/2026/#harvard-pilgrim-excludes-all-weight-loss-drugs-bcbs-20262026-09-15T03:59:43Zweekly https://semaglutides.org/news/2026/#lilly-publishes-updated-list-prices-incretin-portfolio-20262026-09-15T03:59:40Zweekly https://semaglutides.org/news/2026/#mounjaro-joins-chinas-national-reimbursement-drug-list-20262026-09-15T03:59:46Zweekly https://semaglutides.org/news/2026/#north-dakota-becomes-state-require-aca-marketplace-small-20262026-09-15T03:59:50Zweekly https://semaglutides.org/news/2026/#employer-coverage-cuts-drive-surge-insurance-denial-appeal-20262026-09-15T04:00:11Zweekly https://semaglutides.org/news/2026/#suicidal-behavior-ideation-warning-removed-wegovy-label-20262026-09-15T04:00:07Zweekly https://semaglutides.org/news/2025/#oprah-reveals-she-stopped-glp-1s-regained-20-20252026-09-15T03:14:06Zweekly https://semaglutides.org/news/2025/#novo-worst-year-20252026-09-15T04:00:19Zweekly https://semaglutides.org/news/2025/#cms-introduces-balance-model-glp-1-coverage-medicare-20252026-09-15T03:14:15Zweekly https://semaglutides.org/news/2025/#fda-approval-wegovy-pill-opens-highest-growth-query-20252026-09-15T03:14:20Zweekly https://semaglutides.org/news/2025/#wegovy-pill-approved-20252026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/#fda-expands-mounjaro-children-aged-10-older-20252026-09-15T03:14:21Zweekly https://semaglutides.org/news/2025/#journal-marketing-research-publishes-definitive-glp-1-grocery-20252026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/#novo-nordisk-files-cagrisema-fda-20252026-09-15T03:14:41Zweekly https://semaglutides.org/news/2025/#orforglipron-holds-weight-loss-patients-switch-off-injections-20252026-09-15T03:14:57Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-tirzepatide-non-inferior-dulaglutide-20252026-09-15T03:14:51Zweekly https://semaglutides.org/news/2025/#cagrisema-nda-filed-20252026-09-15T04:00:18Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-england-journal-medicine-2025-22026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/#mdl-3163-created-20252026-09-15T03:15:06Zweekly https://semaglutides.org/news/2025/#jpml-creates-mdl-3163-eli-lillys-motion-declining-20252026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/#mounjaro-approved-children-10-older-type-2-diabetes-20252026-09-15T03:15:12Zweekly https://semaglutides.org/news/2025/#retatrutide-delivers-71-2-pounds-average-weight-loss-20252026-09-15T03:15:15Zweekly https://semaglutides.org/news/2025/#retatrutides-phase-3-win-28-7-weight-loss-20252026-09-15T03:15:25Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-england-journal-medicine-20252026-09-15T03:15:31Zweekly https://semaglutides.org/news/2025/#nejm-perspective-calls-generic-liraglutide-overlooked-option-20252026-09-15T04:00:17Zweekly https://semaglutides.org/news/2025/#lilly-alabama-6b-20252026-09-15T04:00:22Zweekly https://semaglutides.org/news/2025/#periods-opens-properly-powered-trial-tirzepatide-pcos-20252026-09-15T04:00:38Zweekly https://semaglutides.org/news/2025/#safe-drugs-act-2025-introduced-congress2026-09-15T04:00:40Zweekly https://semaglutides.org/news/2025/#adas-2026-standards-care-name-semaglutide-tirzepatide-preferred-20252026-09-15T03:15:35Zweekly https://semaglutides.org/news/2025/#redefine-4-completes-novo-nordisks-cagrisema-tested-directly-20252026-09-15T04:00:53Zweekly https://semaglutides.org/news/2025/#structure-therapeutics-15-3-weight-loss-oral-aleniglipron-20252026-09-15T04:00:52Zweekly https://semaglutides.org/news/2025/#fda-seizes-counterfeit-ozempic-labeled-authentic-lot-number-20252026-09-15T03:15:33Zweekly https://semaglutides.org/news/2025/#ftc-approves-final-order-against-telehealth-provider-nextmed-20252026-09-15T03:15:32Zweekly https://semaglutides.org/news/2025/#evoke-ctad-presentation-20252026-09-15T04:00:52Zweekly https://semaglutides.org/news/2025/#analysis-shows-aca-marketplace-glp-1-coverage-shrinking-20252026-09-15T04:00:45Zweekly https://semaglutides.org/news/2025/#faers-analysis-counts-hundreds-compounded-tirzepatide-adverse-events-20252026-09-15T04:01:12Zweekly https://semaglutides.org/news/2025/#eli-lilly-cuts-zepbound-single-dose-vial-prices-20252026-09-15T03:15:45Zweekly https://semaglutides.org/news/2025/#mayo-clinic-proceedings-puts-gi-side-effect-rates-20252026-09-15T04:01:07Zweekly https://semaglutides.org/news/2025/#mounjaro-adds-pediatric-indication-severe-gastrointestinal-adverse-reactions-20252026-09-15T03:16:02Zweekly https://semaglutides.org/news/2025/#cornell-numerator-quantify-how-glp-1-use-changes-20252026-09-15T04:01:08Zweekly https://semaglutides.org/news/2025/#oculus-trial-randomizes-patients-hold-continue-their-glp-20252026-09-15T04:01:17Zweekly https://semaglutides.org/news/2025/#cms-negotiated-price-semaglutide-20252026-09-15T03:16:06Zweekly https://semaglutides.org/news/2025/#circana-projects-glp-1-households-will-drive-third-20252026-09-15T04:01:21Zweekly https://semaglutides.org/news/2025/#evoke-alzheimers-failure-20252026-09-15T03:16:01Zweekly https://semaglutides.org/news/2025/#lizzo-ozempic-boom-erasing-plus-size-people-20252026-09-15T04:01:24Zweekly https://semaglutides.org/news/2025/#eli-lilly-becomes-drugmaker-worth-1-trillion-20252026-09-15T03:16:03Zweekly https://semaglutides.org/news/2025/#novo-199-intro-offer-20252026-09-15T03:16:08Zweekly https://semaglutides.org/news/2025/#kff-finds-18-adults-have-ever-used-glp-20252026-09-15T03:16:16Zweekly https://semaglutides.org/news/2025/#novo-egm-board-takeover-20252026-09-15T03:16:30Zweekly https://semaglutides.org/news/2025/#extraordinary-general-meeting-installs-lars-rebien-sorensen-chair-20252026-09-15T04:01:41Zweekly https://semaglutides.org/news/2025/#pfizer-closes-metsera-20252026-09-15T04:01:34Zweekly https://semaglutides.org/news/2025/#real-world-study-finds-semaglutide-tirzepatide-equally-protective-20252026-09-15T04:01:40Zweekly https://semaglutides.org/news/2025/#pfizer-wins-metsera-20252026-09-15T03:16:36Zweekly https://semaglutides.org/news/2025/#lilly-agrees-trump-administration-cut-zepbound-prices-20252026-09-15T03:16:34Zweekly https://semaglutides.org/news/2025/#mfn-glp1-pricing-deal-20252026-09-15T03:16:42Zweekly https://semaglutides.org/news/2025/#lilly-government-agree-tirzepatide-pricing-including-50-medicare-20252026-09-15T03:16:40Zweekly https://semaglutides.org/news/2025/#trump-glp-1-price-deals-calls-them-fat-20252026-09-15T03:16:49Zweekly https://semaglutides.org/news/2025/#white-house-deal-sets-245-medicare-price-trumprx-20252026-09-15T03:17:03Zweekly https://semaglutides.org/news/2025/#eloralintide-phase-2-results-published-moving-lilly-beyond-20252026-09-15T04:01:47Zweekly https://semaglutides.org/news/2025/#eloralintide-phase-2-20-percent-20252026-09-15T04:01:51Zweekly https://semaglutides.org/news/2025/#lillys-amylin-analog-eloralintide-shows-20-1-weight-20252026-09-15T04:01:51Zweekly https://semaglutides.org/news/2025/#mfn-tariff-relief-vouchers-20252026-09-15T04:02:00Zweekly https://semaglutides.org/news/2025/#rfk-jr-reverses-course-backs-expanded-glp-1-20252026-09-15T04:02:08Zweekly https://semaglutides.org/news/2025/#metsera-bidding-war-20252026-09-15T04:02:17Zweekly https://semaglutides.org/news/2025/#stat-news-documents-glp-1-microdosing-boom-20252026-09-15T04:02:13Zweekly https://semaglutides.org/news/2025/#annals-internal-medicine-study-finds-tirzepatide-semaglutide-have-20252026-09-15T04:02:19Zweekly https://semaglutides.org/news/2025/#zepbound-overtakes-wegovy-20252026-09-15T03:17:07Zweekly https://semaglutides.org/news/2025/#federal-pricing-agreement-cuts-lillys-direct-consumer-zepbound-20252026-09-15T04:02:23Zweekly https://semaglutides.org/news/2025/#federal-pricing-agreement-sets-mounjaro-245-medicare-medicaid-20252026-09-15T04:02:30Zweekly https://semaglutides.org/news/2025/#surmount-4-post-hoc-grades-cardiometabolic-reversal-how-20252026-09-15T04:02:43Zweekly https://semaglutides.org/news/2025/#zepbound-tops-keytruda-20252026-09-15T03:17:05Zweekly https://semaglutides.org/news/2025/#cochrane-review-delivers-cautious-verdict-liraglutide-obesity-20252026-09-15T04:02:45Zweekly https://semaglutides.org/news/2025/#novo-nordisk-unsolicited-counterbid-metsera-20252026-09-15T04:02:50Zweekly https://semaglutides.org/news/2025/#lillydirect-walmart-retail-pickup-direct-consumer-prices-20252026-09-15T04:02:44Zweekly https://semaglutides.org/news/2025/#lillydirect-walmart-pickup-20252026-09-15T04:02:50Zweekly https://semaglutides.org/news/2025/#novo-board-resignations-20252026-09-15T03:17:13Zweekly https://semaglutides.org/news/2025/#rybelsus-cv-indication-20252026-09-15T03:17:12Zweekly https://semaglutides.org/news/2025/#trump-150-glp1-target-20252026-09-15T04:03:04Zweekly https://semaglutides.org/news/2025/#achieve-2-achieve-5-succeed-20252026-09-15T04:03:22Zweekly https://semaglutides.org/news/2025/#synergy-outcomes-mash-phase-3-skips-liver-biopsy-20252026-09-15T04:03:19Zweekly https://semaglutides.org/news/2025/#fda-approves-october-2025-gastrointestinal-labeling-changes-semaglutide2026-09-15T04:03:16Zweekly https://semaglutides.org/news/2025/#novo-nordisk-agrees-buy-akero-therapeutics-5-2-20252026-09-15T04:03:23Zweekly https://semaglutides.org/news/2025/#delaware-court-issues-opinion-lilly-v-strive-pharmacy-20252026-09-15T04:03:23Zweekly https://semaglutides.org/news/2025/#novo-nordisk-cutting-9-000-jobs-worldwide-20252026-09-15T04:03:32Zweekly https://semaglutides.org/news/2025/#network-meta-analysis-56-obesity-drug-trials-published-20252026-09-15T04:03:50Zweekly https://semaglutides.org/news/2025/#study-finds-cost-not-side-effects-main-reason-20252026-09-15T04:03:46Zweekly https://semaglutides.org/news/2025/#va-study-finds-liraglutide-comparable-semaglutide-kidney-heart-20252026-09-15T04:03:48Zweekly https://semaglutides.org/news/2025/#all-semaglutide-labels-gain-severe-gastrointestinal-adverse-reactions-20252026-09-15T03:17:29Zweekly https://semaglutides.org/news/2025/#surpass-peds-published-tirzepatide-cuts-hba1c-2-23-20252026-09-15T04:03:52Zweekly https://semaglutides.org/news/2025/#trumprx-announced-20252026-09-15T03:17:33Zweekly https://semaglutides.org/news/2025/#step-mri-substudy-body-composition-semaglutide-7-2-20252026-09-15T04:03:55Zweekly https://semaglutides.org/news/2025/#court-lets-eli-lillys-personalized-advertising-claim-against-20252026-09-15T04:03:56Zweekly https://semaglutides.org/news/2025/#bmj-group-retracts-apple-cider-vinegar-weight-loss-20252026-09-15T04:04:12Zweekly https://semaglutides.org/news/2025/#lilly-houston-6-5b-20252026-09-15T04:04:19Zweekly https://semaglutides.org/news/2025/#pfizer-agrees-buy-metsera-7-3-billion-20252026-09-15T04:04:18Zweekly https://semaglutides.org/news/2025/#fda-issues-import-alert-66-80-glp-1-20252026-09-15T04:04:23Zweekly https://semaglutides.org/news/2025/#surpass-peds-published-phase-3-tirzepatide-results-children-20252026-09-15T04:04:25Zweekly https://semaglutides.org/news/2025/#oasis-4-published-oral-semaglutide-25-mg-produces-20252026-09-15T03:17:42Zweekly https://semaglutides.org/news/2025/#surpass-cvot-presented-full-easd-2025-vienna2026-09-15T03:17:41Zweekly https://semaglutides.org/news/2025/#orforglipron-beats-oral-semaglutide-head-head-type-2-20252026-09-15T03:17:48Zweekly https://semaglutides.org/news/2025/#oasis-4-published-20252026-09-15T03:17:47Zweekly https://semaglutides.org/news/2025/#achieve-3-topline-20252026-09-15T04:04:27Zweekly https://semaglutides.org/news/2025/#surpass-peds-results-20252026-09-15T04:04:46Zweekly https://semaglutides.org/news/2025/#attain-1-published-lillys-oral-glp-1-pill-20252026-09-15T03:17:54Zweekly https://semaglutides.org/news/2025/#fda-hhs-compounder-letters-20252026-09-15T03:18:02Zweekly https://semaglutides.org/news/2025/#step-published-semaglutide-7-2-mg-pushes-weight-20252026-09-15T03:18:10Zweekly https://semaglutides.org/news/2025/#novo-9000-layoffs-20252026-09-15T03:18:18Zweekly https://semaglutides.org/news/2025/#fda-ad-warning-letters-20252026-09-15T03:18:22Zweekly https://semaglutides.org/news/2025/#fda-sends-hims-hers-warning-letter-compounded-semaglutide-20252026-09-15T03:18:14Zweekly https://semaglutides.org/news/2025/#dtc-advertising-eo-20252026-09-15T04:04:49Zweekly https://semaglutides.org/news/2025/#fda-warning-letters-cite-eli-lilly-minimizing-zepbound-20252026-09-15T04:04:54Zweekly https://semaglutides.org/news/2025/#fda-warns-novo-nordisk-oprah-special-video-20252026-09-15T04:04:57Zweekly https://semaglutides.org/news/2025/#fda-creates-glp-1-api-green-list-import-20252026-09-15T03:18:29Zweekly https://semaglutides.org/news/2025/#nc-medicaid-will-stop-covering-glp-1s-weight-20252026-09-15T04:04:48Zweekly https://semaglutides.org/news/2025/#truveta-quantifies-switching-caused-zepbound-exclusion-20252026-09-15T04:04:51Zweekly https://semaglutides.org/news/2025/#byetta-bydureon-approvals-formally-cease-exist-20252026-09-15T04:05:24Zweekly https://semaglutides.org/news/2025/#patients-file-erisa-class-action-zepbound-formulary-removal-20252026-09-15T04:05:23Zweekly https://semaglutides.org/news/2025/#lilly-raises-uk-mounjaro-list-prices-170-20252026-09-15T04:05:16Zweekly https://semaglutides.org/news/2025/#gallup-obesity-rate-falling-37-0-glp-1-20252026-09-15T03:18:33Zweekly https://semaglutides.org/news/2025/#tricare-ends-weight-loss-drug-coverage-tricare-life-20252026-09-15T04:05:20Zweekly https://semaglutides.org/news/2025/#denmark-halves-2025-growth-forecast-citing-novo-nordisk2026-09-15T04:05:24Zweekly https://semaglutides.org/news/2025/#teva-generic-glp-1-indicated-weight-loss-20252026-09-15T03:18:37Zweekly https://semaglutides.org/news/2025/#obesity-pillars-publishes-concrete-nutrition-numbers-glp-1-20252026-09-15T04:05:28Zweekly https://semaglutides.org/news/2025/#attain-2-completes-orforglipron-obesity-package-20252026-09-15T03:18:40Zweekly https://semaglutides.org/news/2025/#serena-williams-goes-public-zepbound-joins-ro-20252026-09-15T03:18:53Zweekly https://semaglutides.org/news/2025/#eli-lilly-asks-jpml-centralize-glp-1-vision-20252026-09-15T04:05:51Zweekly https://semaglutides.org/news/2025/#ozempic-499-cash-20252026-09-15T04:05:48Zweekly https://semaglutides.org/news/2025/#wegovy-mash-approval-20252026-09-15T03:18:54Zweekly https://semaglutides.org/news/2025/#mdl-objective-testing-20252026-09-15T03:18:58Zweekly https://semaglutides.org/news/2025/#lilly-uk-mounjaro-price-hike-20252026-09-15T04:05:55Zweekly https://semaglutides.org/news/2025/#novo-nordisk-expands-legal-campaign-against-compounded-semaglutide-20252026-09-15T04:05:53Zweekly https://semaglutides.org/news/2025/#target-trial-emulation-finds-semaglutide-tirzepatide-linked-higher-20252026-09-15T04:05:55Zweekly https://semaglutides.org/news/2025/#attain-1-topline-27-3-pounds-lost-highest-20252026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/#doustdar-becomes-ceo-20252026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/#lilly-q2-2025-results-20252026-09-15T04:05:58Zweekly https://semaglutides.org/news/2025/#orforglipron-attain-20252026-09-15T04:06:24Zweekly https://semaglutides.org/news/2025/#orforglipron-delivers-27-3-pounds-average-weight-loss-20252026-09-15T04:06:16Zweekly https://semaglutides.org/news/2025/#novo-guidance-cut-august-20252026-09-15T04:06:25Zweekly https://semaglutides.org/news/2025/#fda-withdraws-byetta-bydureon-approvals-20252026-09-15T04:06:27Zweekly https://semaglutides.org/news/2025/#mdl-judge-rules-what-evidence-supports-gastroparesis-claim-20252026-09-15T03:19:14Zweekly https://semaglutides.org/news/2025/#wegovy-label-adds-acute-kidney-injury-warning-20252026-09-15T04:06:31Zweekly https://semaglutides.org/news/2025/#wegovys-indications-section-rewritten-without-bmi-numbers-20252026-09-15T04:06:36Zweekly https://semaglutides.org/news/2025/#lilly-surpass-cvot-topline-non-inferior-heart-events-20252026-09-15T03:19:18Zweekly https://semaglutides.org/news/2025/#surpass-cvot-topline-20252026-09-15T03:19:24Zweekly https://semaglutides.org/news/2025/#white-house-sends-pricing-demand-letters-drugmakers-20252026-09-15T04:06:47Zweekly https://semaglutides.org/news/2025/#profit-warning-wipes-70-billion-off-novo-nordisks-20252026-09-15T03:19:26Zweekly https://semaglutides.org/news/2025/#dr-reddys-generic-plan-20252026-09-15T04:06:50Zweekly https://semaglutides.org/news/2025/#surmount-5-confirms-tirzepatide-beats-semaglutide-weight-head-20252026-09-15T03:20:38Zweekly https://semaglutides.org/news/2025/#cvs-caremark-forces-largest-molecule-switch-class-date-20252026-09-15T03:19:46Zweekly https://semaglutides.org/news/2025/#cvs-zepbound-class-action-20252026-09-15T03:19:47Zweekly https://semaglutides.org/news/2025/#fda-lists-intestinal-obstruction-fecal-impaction-class-signal-20252026-09-15T04:06:57Zweekly https://semaglutides.org/news/2025/#who-naion-statement-20252026-09-15T04:06:49Zweekly https://semaglutides.org/news/2025/#lilly-commit-trials-pairing-tirzepatide-biologic-inflammatory-bowel-20252026-09-15T04:07:01Zweekly https://semaglutides.org/news/2025/#novo-ends-hims-deal-20252026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/#adjust-t1d-randomized-evidence-semaglutide-type-1-diabetes-20252026-09-15T04:07:07Zweekly https://semaglutides.org/news/2025/#maritide-ada-20252026-09-15T04:07:24Zweekly https://semaglutides.org/news/2025/#60-insurers-pledge-simplify-prior-authorization-20252026-09-15T04:07:22Zweekly https://semaglutides.org/news/2025/#redefine-1-2-published-cagrisema-passes-20-weight-20252026-09-15T03:19:56Zweekly https://semaglutides.org/news/2025/#surmount-mmo-design-published-incretin-outcome-trial-covering-20252026-09-15T04:07:21Zweekly https://semaglutides.org/news/2025/#achieve-1-nejm-ada-20252026-09-15T04:07:26Zweekly https://semaglutides.org/news/2025/#step-up-7-2mg-data-20252026-09-15T04:07:27Zweekly https://semaglutides.org/news/2025/#lizzo-admits-she-tried-ozempic-denials-20252026-09-15T04:07:45Zweekly https://semaglutides.org/news/2025/#asmbs-head-head-study-finds-bariatric-surgery-far-20252026-09-15T04:07:43Zweekly https://semaglutides.org/news/2025/#lilly-offers-every-zepbound-dose-single-dose-vial-20252026-09-15T04:07:49Zweekly https://semaglutides.org/news/2025/#ema-naion-conclusion-20252026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/#federal-judge-rules-fda-novo-merits-semaglutide-shortage-20252026-09-15T03:20:18Zweekly https://semaglutides.org/news/2025/#amycretin-phase-3-20252026-09-15T04:07:56Zweekly https://semaglutides.org/news/2025/#surpass-cvot-completes-four-follow-20252026-09-15T04:07:59Zweekly https://semaglutides.org/news/2025/#cleveland-clinic-study-explains-trial-versus-real-world-20252026-09-15T03:20:17Zweekly https://semaglutides.org/news/2025/#ema-adds-sudden-vision-loss-european-semaglutide-labels-20252026-09-15T03:20:12Zweekly https://semaglutides.org/news/2025/#ema-declares-naion-very-rare-side-effect-semaglutide-20252026-09-15T03:21:21Zweekly https://semaglutides.org/news/2025/#china-approves-mazdutide-worlds-glp-1-glucagon-dual-20252026-09-15T04:08:02Zweekly https://semaglutides.org/news/2025/#503b-deadline-20252026-09-15T03:20:29Zweekly https://semaglutides.org/news/2025/#fdas-compounding-allowance-semaglutide-expires-20252026-09-15T04:08:09Zweekly https://semaglutides.org/news/2025/#connecticuts-attorney-general-warns-clinics-spas-tirzepatide-products-20252026-09-15T04:08:40Zweekly https://semaglutides.org/news/2025/#novo-ceo-ousted-20252026-09-15T03:20:37Zweekly https://semaglutides.org/news/2025/#mfn-executive-order-20252026-09-15T03:20:48Zweekly https://semaglutides.org/news/2025/#surpass-t1d-2-adds-20-long-term-arm-20252026-09-15T04:08:18Zweekly https://semaglutides.org/news/2025/#surmount-5-tirzepatide-beats-semaglutide-head-head-obesity-20252026-09-15T03:20:54Zweekly https://semaglutides.org/news/2025/#district-court-grants-summary-judgment-fda-tirzepatide-case-20252026-09-15T03:21:01Zweekly https://semaglutides.org/news/2025/#court-upholds-fda-authority-tirzepatide-shortage-list-20252026-09-15T04:08:21Zweekly https://semaglutides.org/news/2025/#generic-phentermine-topiramate-er-20252026-09-15T04:08:29Zweekly https://semaglutides.org/news/2025/#weightwatchers-bankruptcy-20252026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/#novo-nordisk-permanent-injunctions-against-compounders-20252026-09-15T04:08:33Zweekly https://semaglutides.org/news/2025/#lilly-withdraws-heart-failure-application-tirzepatide-20252026-09-15T04:08:38Zweekly https://semaglutides.org/news/2025/#cvs-caremark-will-drop-zepbound-standard-commercial-formularies-20252026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/#cvs-wegovy-preferred-20252026-09-15T03:21:16Zweekly https://semaglutides.org/news/2025/#cvs-caremark-zepbound-formulary-removal-producing-largest-forced-20252026-09-15T04:08:52Zweekly https://semaglutides.org/news/2025/#lilly-q1-2025-results-20252026-09-15T04:08:59Zweekly https://semaglutides.org/news/2025/#essence-part-1-shows-semaglutide-reverses-liver-inflammation-20252026-09-15T03:21:24Zweekly https://semaglutides.org/news/2025/#novo-telehealth-partnerships-20252026-09-15T03:21:33Zweekly https://semaglutides.org/news/2025/#charles-barkley-becomes-ros-glp-1-celebrity-ambassador-20252026-09-15T04:08:54Zweekly https://semaglutides.org/news/2025/#gip-receptor-blockade-shown-work-through-different-pathway-20252026-09-15T04:09:04Zweekly https://semaglutides.org/news/2025/#surpass-t1d-1-properly-powered-incretin-trial-type-20252026-09-15T04:09:17Zweekly https://semaglutides.org/news/2025/#federal-court-denies-injunction-sought-compounders-semaglutide-20252026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/#texas-federal-court-leaves-fda-shortage-decision-place-20252026-09-15T04:09:10Zweekly https://semaglutides.org/news/2025/#eli-lilly-sues-four-telehealth-companies-compounded-tirzepatide-20252026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/#503a-deadline-20252026-09-15T03:21:53Zweekly https://semaglutides.org/news/2025/#zepbound-reaches-nearly-339-000-weekly-prescriptions-20252026-09-15T04:09:20Zweekly https://semaglutides.org/news/2025/#achieve-1-topline-20252026-09-15T03:21:48Zweekly https://semaglutides.org/news/2025/#anaesthesia-meta-analysis-retained-stomach-contents-no-measurable-20252026-09-15T03:21:51Zweekly https://semaglutides.org/news/2025/#counterfeit-ozempic-20252026-09-15T04:09:28Zweekly https://semaglutides.org/news/2025/#pfizer-discontinues-oral-glp-1-danuglipron-liver-injury-20252026-09-15T04:09:23Zweekly https://semaglutides.org/news/2025/#itc-issues-general-exclusion-order-infringing-tirzepatide-imports-20252026-09-15T03:22:00Zweekly https://semaglutides.org/news/2025/#fda-seizes-counterfeit-ozempic-supply-chain-20252026-09-15T04:09:30Zweekly https://semaglutides.org/news/2025/#surpass-switch-finds-switching-beats-dose-escalation-people-20252026-09-15T04:09:41Zweekly https://semaglutides.org/news/2025/#meta-analysis-quantifies-weight-regain-stopping-glp-1-20252026-09-15T04:09:46Zweekly https://semaglutides.org/news/2025/#trump-drops-medicare-obesity-proposal-20252026-09-15T04:09:48Zweekly https://semaglutides.org/news/2025/#fda-issues-two-warning-letters-empower-pharmacy-20252026-09-15T04:09:54Zweekly https://semaglutides.org/news/2025/#commerce-opens-section-232-national-security-investigation-pharmaceutical-20252026-09-15T04:09:59Zweekly https://semaglutides.org/news/2025/#lilly-sues-strive-empower-compounded-tirzepatide-20252026-09-15T04:10:05Zweekly https://semaglutides.org/news/2025/#essence-published-semaglutide-resolves-mash-treated-patients-20252026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/#2025-breakthrough-prize-life-sciences-goes-five-glp2026-09-15T04:10:09Zweekly https://semaglutides.org/news/2025/#soul-acc-nejm-20252026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/#stride-pad-results-20252026-09-15T04:10:18Zweekly https://semaglutides.org/news/2025/#enforcement-discretion-ends-503b-outsourcing-facilities-compounding-tirzepatide-20252026-09-15T03:22:22Zweekly https://semaglutides.org/news/2025/#fda-confirms-tirzepatide-compounding-timeline-ruling-20252026-09-15T04:10:15Zweekly https://semaglutides.org/news/2025/#class-action-filed-lemme-glp-1-daily-supplement-20252026-09-15T04:10:27Zweekly https://semaglutides.org/news/2025/#court-denies-compounders-injunction-tirzepatide-20252026-09-15T03:22:23Zweekly https://semaglutides.org/news/2025/#novocare-pharmacy-499-20252026-09-15T03:22:26Zweekly https://semaglutides.org/news/2025/#lilly-27-billion-us-plants-20252026-09-15T03:22:25Zweekly https://semaglutides.org/news/2025/#lilly-cuts-zepbound-cash-price-20252026-09-15T04:10:35Zweekly https://semaglutides.org/news/2025/#surmount-1-dxa-sub-study-puts-numbers-tirzepatide-20252026-09-15T04:10:38Zweekly https://semaglutides.org/news/2025/#outsourcing-facilities-association-sues-fda-semaglutide-delisting-20252026-09-15T04:10:41Zweekly https://semaglutides.org/news/2025/#fda-shortage-resolved-20252026-09-15T03:22:41Zweekly https://semaglutides.org/news/2025/#503a-compounding-tirzepatide-copies-loses-shortage-protection-20252026-09-15T03:22:45Zweekly https://semaglutides.org/news/2025/#enforcement-discretion-ends-503a-pharmacies-compounding-tirzepatide-20252026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/#randomized-trial-semaglutide-alcohol-use-disorder-published-20252026-09-15T03:22:56Zweekly https://semaglutides.org/news/2025/#hims-hers-runs-super-bowl-ad-glp-1-20252026-09-15T03:24:05Zweekly https://semaglutides.org/news/2025/#two-senators-ask-fda-act-hims-hers-super-20252026-09-15T04:10:45Zweekly https://semaglutides.org/news/2025/#lilly-2024-revenue-45-0-billion-32-20252026-09-15T04:10:48Zweekly https://semaglutides.org/news/2025/#scale-kids-published-liraglutide-lowers-bmi-children-aged-20252026-09-15T04:11:03Zweekly https://semaglutides.org/news/2025/#full-2024-results-sales-dkk-290-4-billion-20252026-09-15T04:11:05Zweekly https://semaglutides.org/news/2025/#exenatide-fails-largest-glp-1-trial-parkinsons-disease-20252026-09-15T04:11:05Zweekly https://semaglutides.org/news/2025/#fda-issues-action-letters-both-tirzepatide-kwikpen-applications-20252026-09-15T04:11:12Zweekly https://semaglutides.org/news/2025/#fda-adds-kidney-indication-ozempic-based-flow-20252026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/#ozempic-ckd-approval-20252026-09-15T03:23:12Zweekly https://semaglutides.org/news/2025/#semaglutide-ira-selected-20252026-09-15T03:23:15Zweekly https://semaglutides.org/news/2025/#lancet-commission-proposes-replacing-bmi-based-eligibility-clinical-20252026-09-15T04:11:17Zweekly https://semaglutides.org/news/2025/#three-surmount-1-data-show-93-relative-drop-20252026-09-15T03:23:24Zweekly https://semaglutides.org/news/2025/#medicare-covers-zepbound-osa-20252026-09-15T03:23:19Zweekly https://semaglutides.org/news/2025/#cornell-numerator-quantify-glp-1-grocery-effect-20252026-09-15T03:23:25Zweekly https://semaglutides.org/news/2024/#fda-lists-naion-potential-signal-glp-1-class-20242026-09-15T04:11:25Zweekly https://semaglutides.org/news/2024/#japan-approves-zepbound-obesity-disease-20242026-09-15T04:11:31Zweekly https://semaglutides.org/news/2024/#fda-approves-true-generic-victoza-20242026-09-15T03:23:39Zweekly https://semaglutides.org/news/2024/#cagrisema-redefine1-20242026-09-15T03:23:49Zweekly https://semaglutides.org/news/2024/#zepbound-osa-label-20242026-09-15T03:23:51Zweekly https://semaglutides.org/news/2024/#fda-reaffirms-tirzepatide-shortage-resolved-20242026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/#fda-issues-formal-declaratory-order-ending-tirzepatide-shortage-20242026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/#fda-reaffirms-tirzepatide-shortage-resolution-wind-clocks-20242026-09-15T03:24:10Zweekly https://semaglutides.org/news/2024/#catalent-deal-closes-20242026-09-15T04:11:38Zweekly https://semaglutides.org/news/2024/#european-regulators-conclude-tirzepatide-causes-dysesthesia-delayed-gastric-20242026-09-15T04:11:35Zweekly https://semaglutides.org/news/2024/#rfk-jr-softens-glp-1s-saying-they-have-20242026-09-15T04:11:40Zweekly https://semaglutides.org/news/2024/#fda-issues-what-consultants-describe-only-supplement-side-20242026-09-15T04:11:45Zweekly https://semaglutides.org/news/2024/#rybelsus-r2-approval-20242026-09-15T04:12:03Zweekly https://semaglutides.org/news/2024/#surmount-5-topline-20242026-09-15T03:24:24Zweekly https://semaglutides.org/news/2024/#conagra-puts-glp-1-friendly-label-healthy-choice-20242026-09-15T04:12:03Zweekly https://semaglutides.org/news/2024/#endoscopy-meta-analysis-finds-four-fold-higher-odds-20242026-09-15T04:12:05Zweekly https://semaglutides.org/news/2024/#tennessee-officials-seize-300-counterfeit-glp-1-vials-20242026-09-15T04:12:10Zweekly https://semaglutides.org/news/2024/#glp-1-prescription-volume-passes-9-million-20242026-09-15T04:12:10Zweekly https://semaglutides.org/news/2024/#maritide-phase-2-20242026-09-15T04:12:24Zweekly https://semaglutides.org/news/2024/#cms-proposes-obesity-coverage-20242026-09-15T04:12:36Zweekly https://semaglutides.org/news/2024/#summit-published-aha-20242026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/#three-surmount-1-data-show-94-percent-lower-20242026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/#surmount-1-176-week-detail-20242026-09-15T04:12:33Zweekly https://semaglutides.org/news/2024/#aspiration-warning-appears-semaglutide-tirzepatide-liraglutide-labels-20242026-09-15T03:24:22Zweekly https://semaglutides.org/news/2024/#fda-finalizes-gastrointestinal-aspiration-labeling-mounjaro-20242026-09-15T04:12:39Zweekly https://semaglutides.org/news/2024/#semaglutide-listed-available-20242026-09-15T04:12:35Zweekly https://semaglutides.org/news/2024/#step-9-knee-oa-20242026-09-15T04:12:40Zweekly https://semaglutides.org/news/2024/#five-medical-societies-reverse-course-patients-can-keep-20242026-09-15T03:24:31Zweekly https://semaglutides.org/news/2024/#astrazeneca-discontinues-byetta-united-states-20242026-09-15T03:24:47Zweekly https://semaglutides.org/news/2024/#fda-remands-tirzepatide-shortage-decision-re-evaluation-20242026-09-15T04:12:59Zweekly https://semaglutides.org/news/2024/#novo-ddc-petition-20242026-09-15T04:13:06Zweekly https://semaglutides.org/news/2024/#soul-topline-20242026-09-15T03:24:49Zweekly https://semaglutides.org/news/2024/#fda-letter-signals-enforcement-discretion-during-remand-20242026-09-15T04:13:10Zweekly https://semaglutides.org/news/2024/#court-remands-tirzepatide-shortage-decision-fda-20242026-09-15T04:13:08Zweekly https://semaglutides.org/news/2024/#fda-reconsiders-tirzepatide-delisting-20242026-09-15T04:13:05Zweekly https://semaglutides.org/news/2024/#outsourcing-facilities-association-sues-fda-tirzepatide-shortage-delisting-20242026-09-15T04:13:21Zweekly https://semaglutides.org/news/2024/#ofa-sues-fda-20242026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/#tirzepatide-delisted-shortage-20242026-09-15T03:25:01Zweekly https://semaglutides.org/news/2024/#fda-declares-tirzepatide-shortage-resolved-october-2-20242026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/#lilly-medicine-foundry-20242026-09-15T04:13:30Zweekly https://semaglutides.org/news/2024/#novo-nordisks-ceo-grilled-bernie-sanders-glp-1-20242026-09-15T03:25:07Zweekly https://semaglutides.org/news/2024/#ceo-jorgensen-testifies-senate-help-committee-ozempic-wegovy-20242026-09-15T04:13:35Zweekly https://semaglutides.org/news/2024/#fda-orders-class-wide-anesthesia-warning-glp-1-20242026-09-15T03:25:16Zweekly https://semaglutides.org/news/2024/#fda-issues-section-505-o-4-letter-pulmonary-20242026-09-15T04:13:39Zweekly https://semaglutides.org/news/2024/#lasker-award-honors-glp-1-discovery-20242026-09-15T04:13:45Zweekly https://semaglutides.org/news/2024/#pooled-analysis-suggests-semaglutide-cuts-heart-failure-events-20242026-09-15T04:13:38Zweekly https://semaglutides.org/news/2024/#zepbound-vials-399-20242026-09-15T03:25:18Zweekly https://semaglutides.org/news/2024/#lilly-releases-zepbound-single-dose-vials-20242026-09-15T04:13:53Zweekly https://semaglutides.org/news/2024/#surmount-1-three-year-diabetes-prevention-20242026-09-15T03:25:19Zweekly https://semaglutides.org/news/2024/#fda-all-tirzepatide-doses-available-20242026-09-15T04:13:58Zweekly https://semaglutides.org/news/2024/#summit-hfpef-topline-20242026-09-15T04:14:02Zweekly https://semaglutides.org/news/2024/#step-10-reverses-prediabetes-81-participants-20242026-09-15T04:14:08Zweekly https://semaglutides.org/news/2024/#fda-warns-overdoses-compounded-semaglutide-dosing-errors-20242026-09-15T04:14:06Zweekly https://semaglutides.org/news/2024/#jama-internal-medicine-tirz-vs-sema-20242026-09-15T04:14:13Zweekly https://semaglutides.org/news/2024/#naion-harvard-study-20242026-09-15T03:25:34Zweekly https://semaglutides.org/news/2024/#novo-nordisks-listed-shares-close-all-time-high-20242026-09-15T03:25:33Zweekly https://semaglutides.org/news/2024/#china-approves-wegovy-long-term-weight-management-20242026-09-15T04:14:19Zweekly https://semaglutides.org/news/2024/#fda-approves-generic-qsymia-20242026-09-15T04:14:28Zweekly https://semaglutides.org/news/2024/#teva-authorized-generic-victoza-20242026-09-15T03:25:36Zweekly https://semaglutides.org/news/2024/#novo-nordisk-4-1-billion-plant-clayton-north-20242026-09-15T04:14:28Zweekly https://semaglutides.org/news/2024/#surmount-osa-shows-tirzepatide-roughly-halves-sleep-apnea-20242026-09-15T03:25:48Zweekly https://semaglutides.org/news/2024/#lilly-publishes-open-letter-counterfeit-compounded-tirzepatide-20242026-09-15T03:25:49Zweekly https://semaglutides.org/news/2024/#cell-metabolism-paper-maps-tirzepatides-effects-fat-cells-20242026-09-15T04:14:41Zweekly https://semaglutides.org/news/2024/#synergy-nash-shows-tirzepatide-resolves-fatty-liver-disease-20242026-09-15T04:14:32Zweekly https://semaglutides.org/news/2024/#flow-published-20242026-09-15T03:25:50Zweekly https://semaglutides.org/news/2024/#lilly-indiana-5-3b-20242026-09-15T04:14:44Zweekly https://semaglutides.org/news/2024/#kelly-clarkson-her-weight-loss-drug-not-ozempic-20242026-09-15T04:14:46Zweekly https://semaglutides.org/news/2024/#select-four-data-show-weight-loss-holds-208-20242026-09-15T04:14:58Zweekly https://semaglutides.org/news/2024/#hims-hers-compounded-semaglutide-injections-20242026-09-15T04:14:53Zweekly https://semaglutides.org/news/2024/#kff-finds-12-adults-have-ever-taken-glp-20242026-09-15T04:15:00Zweekly https://semaglutides.org/news/2024/#nestl-vital-pursuit-glp-1-users-20242026-09-15T04:15:04Zweekly https://semaglutides.org/news/2024/#surmount-osa-topline-20242026-09-15T03:26:01Zweekly https://semaglutides.org/news/2024/#ema-suicidality-conclusion-20242026-09-15T04:15:07Zweekly https://semaglutides.org/news/2024/#fda-adds-zepbound-drug-shortage-list-20242026-09-15T04:15:13Zweekly https://semaglutides.org/news/2024/#fda-approves-zepbound-single-dose-vials-20242026-09-15T04:15:22Zweekly https://semaglutides.org/news/2024/#whoopi-goldberg-sunny-hostin-disclose-mounjaro-use-view-20242026-09-15T04:15:27Zweekly https://semaglutides.org/news/2024/#oprah-glp1-special-20242026-09-15T03:26:08Zweekly https://semaglutides.org/news/2024/#zepbound-new-scripts-pass-wegovy-20242026-09-15T04:15:31Zweekly https://semaglutides.org/news/2024/#lilly-runs-big-night-shame-oscar-night-20242026-09-15T04:15:28Zweekly https://semaglutides.org/news/2024/#wegovy-cv-indication-20242026-09-15T03:26:24Zweekly https://semaglutides.org/news/2024/#zepbound-passes-wegovy-weekly-prescriptions-time-20242026-09-15T03:26:16Zweekly https://semaglutides.org/news/2024/#market-capitalization-passes-600-billion-amycretin-data-20242026-09-15T04:15:38Zweekly https://semaglutides.org/news/2024/#evernorth-pbm-financial-guarantee-glp-1-spend-20242026-09-15T04:15:42Zweekly https://semaglutides.org/news/2024/#lilly-impurity-warning-knockoffs-20242026-09-15T04:15:45Zweekly https://semaglutides.org/news/2024/#flow-topline-20242026-09-15T03:26:23Zweekly https://semaglutides.org/news/2024/#s-lite-only-controlled-test-exercise-glp-1-20242026-09-15T04:16:00Zweekly https://semaglutides.org/news/2024/#oprah-winfrey-leaves-weightwatchers-board-20242026-09-15T04:16:00Zweekly https://semaglutides.org/news/2024/#novo-catalent-deal-announced-20242026-09-15T03:26:18Zweekly https://semaglutides.org/news/2024/#mdl-3094-created-20242026-09-15T03:26:34Zweekly https://semaglutides.org/news/2024/#jpml-creates-mdl-3094-eli-lilly-named-defendant-20242026-09-15T03:26:43Zweekly https://semaglutides.org/news/2024/#full-2023-results-sales-31-dkk-232-3-20242026-09-15T04:15:59Zweekly https://semaglutides.org/news/2024/#fda-finds-no-evidence-glp-1-drugs-cause-20242026-09-15T04:16:02Zweekly https://semaglutides.org/news/2024/#north-carolina-state-health-plan-votes-drop-glp-20242026-09-15T04:16:19Zweekly https://semaglutides.org/news/2024/#fda-suicidality-review-20242026-09-15T04:16:12Zweekly https://semaglutides.org/news/2024/#lilly-lillydirect-direct-patient-platform-major-drugmaker-20242026-09-15T03:26:46Zweekly https://semaglutides.org/news/2024/#lillydirect-launch-detail-20242026-09-15T03:26:47Zweekly https://semaglutides.org/news/2024/#lillydirect-launch-20242026-09-15T04:16:30Zweekly https://semaglutides.org/news/2024/#nature-medicine-suicidality-20242026-09-15T04:16:34Zweekly https://semaglutides.org/news/2023/#fda-seizes-thousands-counterfeit-ozempic-pens-20232026-09-15T04:16:32Zweekly https://semaglutides.org/news/2023/#surmount-4-jama-20232026-09-15T03:27:00Zweekly https://semaglutides.org/news/2023/#european-commission-adds-chronic-weight-management-mounjaro-20232026-09-15T04:16:34Zweekly https://semaglutides.org/news/2023/#zepbound-pharmacy-launch-20232026-09-15T04:16:39Zweekly https://semaglutides.org/news/2023/#surmount-4-confirms-rapid-regain-stopping-tirzepatide-20232026-09-15T04:16:47Zweekly https://semaglutides.org/news/2023/#oprah-winfrey-tells-people-she-uses-weight-loss-20232026-09-15T03:26:51Zweekly https://semaglutides.org/news/2023/#select-aha-nejm-20232026-09-15T03:27:06Zweekly https://semaglutides.org/news/2023/#fda-approves-zepbound-20232026-09-15T03:27:18Zweekly https://semaglutides.org/news/2023/#zepbound-approved-weight-management-carrying-suicidal-ideation-warning-20232026-09-15T03:27:22Zweekly https://semaglutides.org/news/2023/#zepbound-approval-label-20232026-09-15T03:27:16Zweekly https://semaglutides.org/news/2023/#mhra-mounjaro-weight-loss-20232026-09-15T04:16:59Zweekly https://semaglutides.org/news/2023/#zepbound-approval-splits-tirzepatide-search-demand-two-brand-20232026-09-15T04:17:08Zweekly https://semaglutides.org/news/2023/#zepbound-1-059-87-flat-all-doses-20232026-09-15T04:17:10Zweekly https://semaglutides.org/news/2023/#ema-requests-suicidality-data-20232026-09-15T04:17:03Zweekly https://semaglutides.org/news/2023/#sharon-osbourne-warns-ozempic-dropping-below-100-pounds-20232026-09-15T04:17:10Zweekly https://semaglutides.org/news/2023/#lilly-files-section-337-complaint-itc-against-11-20232026-09-15T04:17:17Zweekly https://semaglutides.org/news/2023/#surmount-3-lancet-20232026-09-15T04:17:30Zweekly https://semaglutides.org/news/2023/#jama-research-letter-links-glp-1-weight-loss-20232026-09-15T03:27:26Zweekly https://semaglutides.org/news/2023/#walmart-glp-1-users-buying-less-food-20232026-09-15T03:27:28Zweekly https://semaglutides.org/news/2023/#goldman-sachs-sizes-anti-obesity-drug-market-100-20232026-09-15T04:17:28Zweekly https://semaglutides.org/news/2023/#ozempic-ileus-warning-20232026-09-15T03:27:36Zweekly https://semaglutides.org/news/2023/#lilly-first-compounding-suits-20232026-09-15T04:17:40Zweekly https://semaglutides.org/news/2023/#novo-most-valuable-europe-20232026-09-15T03:27:56Zweekly https://semaglutides.org/news/2023/#step-hfpef-published-20232026-09-15T04:17:40Zweekly https://semaglutides.org/news/2023/#select-topline-20232026-09-15T03:27:50Zweekly https://semaglutides.org/news/2023/#first-gastroparesis-suits-20232026-09-15T04:17:34Zweekly https://semaglutides.org/news/2023/#surmount-3-4-topline-20232026-09-15T04:17:45Zweekly https://semaglutides.org/news/2023/#liraglutide-injection-goes-fda-drug-shortage-list-20232026-09-15T04:17:59Zweekly https://semaglutides.org/news/2023/#tirzepatide-labeling-changed-add-ileus-alongside-similar-semaglutide-20232026-09-15T04:18:08Zweekly https://semaglutides.org/news/2023/#asa-tells-anesthesiologists-hold-glp-1-drugs-elective-20232026-09-15T04:18:02Zweekly https://semaglutides.org/news/2023/#retatrutide-phase-2-nejm-20232026-09-15T03:27:51Zweekly https://semaglutides.org/news/2023/#oasis-1-shows-daily-semaglutide-pill-can-match-20232026-09-15T04:18:10Zweekly https://semaglutides.org/news/2023/#surmount-2-tirzepatide-weight-loss-type-2-diabetes-20232026-09-15T04:18:07Zweekly https://semaglutides.org/news/2023/#orforglipron-phase-2-nejm-20232026-09-15T04:18:15Zweekly https://semaglutides.org/news/2023/#phase-2-obesity-results-14-7-weight-loss-20232026-09-15T04:18:36Zweekly https://semaglutides.org/news/2023/#novo-first-compounding-lawsuits-20232026-09-15T04:18:24Zweekly